


Handbook of Pathology Services



Fourth Edition
2026

Editors

Mr. Alex C.P. Leung

Ms. Christina S.M. Long Leung

Mr. Thomas H.C. Wong

Copies of this handbook can be obtained from the secretary of the Department of Pathology.
A web version is also available at "Department of Pathology" on <https://www.hksh-hospital.com>.

Produced with the Support of
Everest Medicines II (HK) Limited



Standing (left to right):

Jack Lam, Dr. Raymond Chan DHSc, Ryon Heung, Patrick Lam, Chan Tsz Ming, Thomas Wong, Lo Yun Chuen, Dr. Jerry Ng, Dr. Tony Ma, Dickson Ngai, Dr. Thomas Wan PhD, Kith Tsui, Dr. Tommy Au PhD, Esda Ng, Lau Yin See, Christina Long, Kristi Lai

Seated (left to right):

Dr. John Nicholls, Dr. Robert Collins (Deputy Director), Dr. May Chan, Dr. Annie Cheung, Dr. Chan Wai Kong (Director of Histopathology & Cytology Division), Dr. Laurence Hou (Senior Advisor), Dr. Tsao Yen Chow (Head (Administrative)), Dr. Edmond Ma (Director of Clinical Pathology & Molecular Pathology Division), Dr. Bone Tang (Deputy Director), Dr. William Choi, Dr. Jonpaul Zee, Dr. Melody Hui and Mr. Alex Leung (Senior Medical Technologist Lab in-charge)

TABLE OF CONTENTS

Preface	4	Confidentiality of Data	14	Clinical Immunology	50	Health Assessment Packages	82
Introduction	6	Care and Respect of Specimen	14	Core Laboratory Service	59	Test Panels / Packages	84
General Information		Test Turnaround Time	15	Stem Cell	60	Guidelines / Patient Notes for Special Tests	87
Hours of Operation	8	Unlisted Tests	15	Flow Cytometry	61	Appendix	90
Useful Contact Numbers	9	Point-of-Care Testing (POCT)	15	Sleep Test Laboratory	62	Index	96
How to Order Lab Tests	11	Test Disciplines		Histopathology and Cytology Division			
Patient Identification Policy	12	Clinical Pathology Division		Histopathology	63		
Standard Precautions for Specimen Handling	12	Blood Bank	17	Cytology – Gynaecological	65		
Rejection of Unacceptable Specimens	13	General Laboratory and Send-out Test Services	18	Cytology – Non-gynaecological	66		
Unsatisfactory Analytic Results	13	Clinical Chemistry	19	Molecular Pathology Division			
Critical Value Reporting Policy	14	Clinical Haematology	43	Infectious Disease	68		
Policy for the Disclosure of Results	14	Clinical Microbiology	47	Molecular Haematopathology	71		
				Molecular Oncology	77		



PREFACE

**Clinical
Pathology**

**Histopathology
and
Cytology**

**Molecular
Pathology**

With the rapid expansion of clinical services and the ever-increasing demand for pathology support from different sub-specialty groups, it has become imperative that we publish a new edition of the Handbook in order to accommodate all the new information that has accumulated. Nevertheless, the aim of our Department remains the same, i.e. to provide fast, reliable and comprehensive services. The Handbook remains a tool for easy reference to the wide range of services in our Department.

Of late, HKSH Medical Group has been popularising the concept of 'clinical partnership in care'. This applies not just to the cooperation between doctors and nurses but also among all members of the Group including allied health professionals and laboratories. In order to provide a better and reliable service, good communication must be maintained between users and the laboratory. We welcome information and feedback from all clinical staff.

Already, we have 2 pathologists in haematology, 3 pathologists in microbiology and 8 histopathologists collaborating closely with the clinicians. Our molecular laboratory also works hand in hand with our clinicians. Other aspects of laboratory services, including the service standard, turnaround time, etc., have also been looked into.

We hope this Handbook will continue to serve as a ready reference for you. A soft copy is available for download under the "Department of Pathology" at our Hospital's website.

Dr. Y. C. Tsao

Administrative Director
Department of Pathology

March 2026

INTRODUCTION

The Fourth Edition of this handbook comes at a time when great strides are made in laboratory medicine, in which laboratory testing is not only reserved for diagnostic purposes but also intended to support clinicians in disease prognostication, treatment guidance, monitoring of progress and disease prevention. The laboratory closely partners with clinicians in the advancement of patient care and management.

Like the previous edition, the Fourth Edition of the Handbook of Pathology Services is prepared with the laboratory users in mind, aiming to assist them in making the best use of the Pathology Services offered by HKSH Medical Group. Through consulting this booklet, laboratory investigations relevant to various body systems or clinical specialties can be selected and ordered.

Proper adherence to sample collection and handling guidelines will ensure accurate results with minimal delay. General procedures of requesting laboratory tests are described in the initial sections. Special attention must be drawn to the fact that serious errors can occur as a result of patient misidentification. Hence we urge the proper completion of sample requisition form with the appropriate patient identifiers and clinical information. Our pathologists, scientists and technologists are always ready to assist in laboratory test selection.

There has been impressive expansion of Molecular Pathology service that covers the scope of oncology testing, rapid infectious disease diagnostics and genetic testing. The Division of Molecular Pathology is equipped with state-of-the-art genome sequencers, automated molecular systems and cytogenomic workstations that enable the application of precision medicine to serve patient needs.

Point-of-care testing devices are introduced in the Hospital to guide patient management decisions at the bedside. The Clinical Laboratory is responsible for instrument evaluation and quality assurance of these devices.

The complete list of laboratory tests can be found in subsequent sections grouped in disciplines under the three divisions of the Department. Test information includes test names, sample requirements, methodologies, test frequency, test turnaround time and special remarks. We are only providing brief information of each test for easy referencing. More detailed specifications and indications of special tests are available under the "Pathology Services Update" in the Doctors Corner of the Hospital's homepage.

Besides laboratory diagnostics, we are also involved in direct patient-related services, namely phlebotomy, urea breath testing, sleep apnoea (polysomnography), and electrocardiography. The Clinical Laboratory is a certified phlebotomy training centre recognised by the American Society of Clinical Pathology.

In order to achieve and maintain excellent standard of services, the Department of Pathology emphasises quality management, staff training, external accreditation and communication. By adhering strictly to official occupation safety and health guidelines, we strive to provide a safe environment for staff through the minimisation and management of workplace hazards and anticipation of risks.

Medical and technical staff of the Department is prepared to provide help and advice on the available laboratory investigations. As always, we welcome any comments and suggestions, and are committed to providing pathology services of the highest standards, to the ultimate benefit of our patients.

Dr. Edmond S. K. Ma

Director of Clinical Pathology & Molecular Pathology Division



Hours of Operation

	Normal Service	Outside Office Hours
Clinical Pathology Division Blood Bank Clinical Chemistry Clinical Haematology Clinical Microbiology	24 hours a day, 7 days a week	
Clinical Pathology Division, Island East	24 hours a day, 7 days a week	
Clinical Immunology and Serology	8:00 am to 4:00 pm Monday to Saturday	N/A
Stem Cell	9:00 am to 5:00 pm Weekday 9:00 am to 1:00pm Saturday	N/A
Send-out Tests	9:00 am to 5:00 pm Weekday 9:00 am to 1:00pm Saturday	N/A
Histopathology and Cytology Division	8:00 am to 6:00 pm Weekday 8:00 am to 6:00 pm Saturday	Frozen section cases at an extra charge
Molecular Pathology Division	8:00 am to 6:00 pm Weekday 8:00 am to 6:00 pm Saturday	On call for special cases

Useful Contact Numbers

Administrative Director

Dr. Tsao Yen Chow 2835-8800

Director, Clinical and Molecular Pathology Division

Dr. Ma Shiu Kwan, Edmond..... 2835-8017

Director, Histopathology and Cytology Division

Dr. Chan Wai Kong 2835-8772

Clinical Microbiologist

Dr. Yung Wai Hung, Raymond..... 2835-8800

Dr. Tang Siu Fai, Bone 2835-8969

Dr. Zee Sze Tsing, Jonpaul..... 2835-7064

Consultant Haematologist

Dr. Choi Wai Lap, William 2835-8499

Consultant Histopathologist

Dr. Chan Kwok Mei, May 2835-8771

Dr. Collins, Robert John 2835-7691

Dr. Ma Kwok Fai, Tony 2835-8775

Dr. Hui Yin, Melody..... 2835-7692

Dr. Nicholls, John Malcolm 2835-7848

Dr. Cheung Nga Yin, Annie..... 2835-5547

Dr. Ng Ping Wing, Jerry..... 2835-8775

Senior Medical Technologist In-charge

Mr. Leung Chin Pang, Alex 2835-8798

Blood Bank

Ms. Ng Hon Yi, Esda 2835-8793

Clinical Chemistry

Mr. Lo Yun Chuen 2835-7083

Clinical Haematology

Ms. Lau Yin See 2835-8795

Clinical Microbiology

Mr. Chan Tsz Ming..... 2835-8791

Clinical Immunology & Serology

Ms. Lai Tsz Wan, Kristi 2835-8796

General Laboratory and Send-out Test Services

Mr. Ngai Cheung, Dickson 2835-8702

Stem Cell

Mr. Wong Hin Ching, Thomas 2835-8412

Sleep Test Laboratory

Mr. Lam Kam Wah, Jack 2835-8702

Clinical Pathology Division, Island East

Mr. Tsui Ka Kit, Kith 2917-5203

Histopathology and Cytology Division

Mr. Lam Chi Wai, Patrick 2835-8839

Molecular Pathology Division

Dr. Au Chun Hang, Tommy (PhD) 2917-5642

General Enquiries

Clinical Pathology 2835-8790

Clinical Pathology Division (Island East) .. 2917-5201

Histopathology and Cytology 2835-8839

Molecular Pathology (Happy Valley) 2835-8779

Molecular Pathology (Island East)..... 2917-5640

Sleep Test Laboratory

..... 2835-8702

Phlebotomy Hotline

..... 2835-8790

Facsimile Number

Clinical Pathology 2835-8799

Clinical Pathology Division (Island East) .. 2892-7408

Histopathology and Cytology 2834-6392

Molecular Pathology (Happy Valley) 2892-7558

Molecular Pathology (Island East)..... 2711-1630

Department Secretary

Ms. Ryon Heung 2835-7032

How to Order Lab Tests

Please use the appropriate request form(s) for test(s) required. Patient demographics must be given, together with the date and time of collection. Appropriate clinical history should be given. The test(s) must be ordered and signed by the attending doctor or attending nurse on his/her behalf. For phlebotomy requests, please send us the form as soon as possible so as to minimise delays in processing.

Under normal circumstances, our team of highly trained phlebotomists is responsible for blood collection of inpatients and outpatients of the Hospital. Due to limited manpower, we might be unable to answer your calls during night time. And for urgent cases, please call the Hospital Operator, and we shall get back to you as soon as possible.

In case of blood collection being done externally by doctors or nurses, please ensure that the blood is placed in appropriate containers for the required tests, clearly labelled with two patient's unique identifiers, specimen type (if appropriate), time of collection (if appropriate) and delivered promptly to our Department for processing. Incorrectly labelled / unidentified samples and forms will be rejected (See Rejection Criteria for details). Specimen must be placed in securely sealed triple packaging during delivery, to which the request forms are also securely attached. (Refer to Standard Precautions for Specimen Handling).

Verbal Request and Amendment of Request

Verbal request or any request for amending laboratory test must be supplemented with a written document.

Request to add test on previous sample is subject to the availability and suitability of the sample .

Patient Identification Policy

It is the Group's policy that services are only rendered to patients upon presentation of valid identification documentations. Those who do not hold a HKID must provide other forms of identification.

Standard Precautions for Specimen Handling

- All specimens should be treated as infectious and handled using standard precautions.
- Specimens must be delivered to the laboratory in "triple-layer packaging" in accordance with the Group's guidelines.
- A leak-proof container must be used as a primary holder of the specimen, packed in a single secondary container.
- All secondary containers should be placed into an outer container or packaging / box during delivery. The outer container should be made of strong material that can be cleansed and disinfected, and should be labelled with biohazard warning signs.
- Appropriate personal protective equipment (PPE) must be worn when handling specimens.

Rejection of Unacceptable Specimens

All efforts will be made in attempting to process specimens. Specimens may be deemed unsuitable or unsafe for processing and thus rejected under the following circumstances:

- Request forms without two unique patient identifiers
- Request forms without indication of test required
- Request forms without the name of requesting doctor
- Request forms with illegible writing
- Request forms contaminated with blood or body fluids
- Specimens without labelling
- Specimens in wrong container type
- Specimen without appropriate additive/ preservative / fixative
- Haemolyzed or insufficient amount of sample
- Spilled specimens, leaking or cracked tubes and containers
- Mismatched information on the forms and specimens

Unsatisfactory Analytic Results

The duty technologist will repeat the test with justification if the result(s) is/are considered doubtful. Second samples are required for repeat testing if the duty supervisor remains unsatisfied with the results.

Critical Value Reporting Policy

Critical values are defined as laboratory results, found in pathological states, that show significant variations from normal ranges and are potentially life-threatening. Laboratory staff will verbally report these results over the phone directly to the doctor-in-charge so that immediate action can be taken. Nurses at of ward/ centre / outside clinics will be informed if the doctor cannot be reached.

Policy for the Disclosure of Results

The Group prohibits disclosure of confidential information to unauthorised parties. Only requesting doctors and other authorised medical staff will receive the results, which are given at the total discretion of the Department of Pathology.

Confidentiality of Data

The Department would like to reassure its users that all laboratory test results and patient data remain fully confidential.

Care and Respect of Specimen

The Department would like to reassure its users that the laboratory shall treat all patients' specimens with due care and respect.

Test Turnaround Time

The turnaround time of laboratory tests varies according to the type of tests required. In general, it ranges from 30 minutes for an urgent CBP to a few weeks for tests sent to other countries. Frequency and turnaround time of each test are provided in this Handbook for reference. As a large number of tests are processed every day, please indicate clearly on the request form if urgent results are expected. We shall make our best effort to cater to your needs.

Unlisted Tests

Please contact the Department at 2835-8702 for tests not listed in this Handbook. We will try our best to search for testing laboratories that suit your needs.

Point-of-Care Testing (POCT)

Point-of-care testing provides rapid critical test results at the patient's bedside, enabling clinicians to make informed treatment decisions promptly. All POCT testing devices are managed by the Department of Pathology, and we strive to provide accurate test instruments through vigorous quality control, maintenance schedules and parallel testing with laboratory instruments. POCT devices are currently available for bedside testing of some vital analytes at the Operating Theatre, Intensive Care Unit, Department of Diagnostic & Interventional Radiology and Cardiac Catheterization & Intervention Centre. For further enquiry, please call 2835-7083.



TEST DISCIPLINES

CLINICAL PATHOLOGY DIVISION

Blood Bank (ext. 8793)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Blood Group Rh (D) typing	Not applicable	EDTA whole blood	Forward & Reverse typing	On arrival	Immuno-haematology	Routine: within 2 hours	
Direct Coombs	Negative	EDTA whole blood	Serology	On arrival	Immuno-haematology	Routine: within 4 hours after receipt of the specimen	
Indirect Coombs	Negative	EDTA whole blood	Serology	On arrival	Immuno-haematology	Routine: within 4 hours	
Cold Agglutinin	<32	Serum	Serology at 4°C	On arrival	Immuno-haematology	1 working day	
Warm Agglutinin	Negative	Serum	Serology at 37°C	On arrival	Immuno-haematology	Routine: within 4 hours	
Warm Agglutinin	Negative	Serum	Serology at 37 °C	On arrival	Immuno-haematology	Urgent: 1 to 1½ hours Routine: within 4 hours	
Crossmatch	Compatible	EDTA whole blood	Serology	On arrival	Immuno-haematology	Routine: within 4 hours	
Type & Screen	No irregular antibodies detected	EDTA whole blood	Serology	On arrival	Immuno-haematology	Routine: within 4 hours	
Private Donor	Suitable for donation	EDTA whole blood	Serology	On request	Blood Transfusion	At least 7 working days	
Autologous Transfusion	Suitable for donation	EDTA whole blood	Serology	On request	Blood Transfusion	At least 7 working days	

General Laboratory and Send-out Test Services (ext. 8702)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Pledge TAT	Remarks
Urea Breath Test	< 4 Delta	Carbon dioxide gas	Infra-red spectrometry	On request	2 working days	Patients should fast for at least 4 hours before testing. Some drugs are restricted, please enquire

Clinical Chemistry sample type notation:

- AF - Ascitic Fluid
CSF - Cerebral Spinal Fluid
EP - EDTA Plasma
F - Fluoride Plasma
HW - Heparinized Whole Blood
S - Serum
WB - Whole Blood
- CP - Citrated Plasma
DF - Drain Fluid
EW - EDTA Whole Blood
HP - Heparinized Plasma
PF - Pleural Fluid
U - Urine
24-hr U - 24 hour Urine

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Active B12	37.5-188 pmol/L	HP	ECLIA	On arrival	Anemia marker	4 hours	
Adrenocorticotrophic hormone (ACTH)	1.6 - 13.9 pmol/L	EP	ECLIA	Every 2 days	Hormone	2 days	Transport on ice, separate from cells asap
Alanine aminotransferase (ALT)	M: ≤50 U/L F: ≤35 U/L	HP	IFCC, with Pyridoxal phosphate	On arrival	Liver	4 hours	
Albumin	40 - 49 g/L	HP	BCG	On arrival	Liver	4 hours	
Alkaline phosphatase (ALP)	M: 40 - 129 U/L F: 35 - 104 U/L	HP	IFCC, AMP buffer	On arrival	Liver	4 hours	
Allergen component IgE	≤0.34 KU/L	S	ImmunoCAP	Twice per week	Allergy	3-7 days	Peanut, Egg, Milk
Alpha-fetoprotein (AFP)	<7.0 µg/L	HP	ECLIA	On arrival	Tumour Marker	4 hours	
Amikacin	Peak (Therapeutic): 34.2 - 42.8 µmol/L Peak (Toxic): >59.9 µmol/L Trough (Therapeutic): 8.6 - 17.1 µmol/L Trough (Toxic): >17.1 µmol/L	S	KIMS	On arrival	Therapeutic drug level	4 hours	
Ammonia	M: 16 - 60 µmol/L F: 11 - 51 µmol/L	EP	Enzymatic	On arrival	Liver	4 hours	Transport on ice, separate from cells asap
Amylase	28 - 100 U/L	HP	IFCC, Enzymatic colorimetric	On arrival	Pancreas	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Amylase (drain fluid)	N/A	DF	IFCC, Enzymatic colorimetric	On arrival	Body fluid	4 hours	
Amylase, pancreatic	13 - 53 U/L	HP	Salivary amylase inhibition	On arrival	Pancreas	4 hours	
Anti-Mullerian Hormone (AMH)	F(20-24 yr): 8.71-83.6 pmol/L F(25-29 yr): 6.35-70.3 pmol/L F(30-34 yr): 4.11-58.0 pmol/L F(35-39 yr): 1.05-53.5 pmol/L F(40-44 yr): 0.19-39.1 pmol/L F(45-50 yr): 0.07-19.3 pmol/L	HP	ECLIA	Twice per week	Fertility Hormone	3 days	
Anti-thyroglobulin	<115 KIU/L	S	ECLIA	On arrival	Thyroid	4 hours	
Apolipoprotein A1	M: 1.10 - 2.05 g/L F: 1.25 - 2.15 g/L	S	Turbidimetry	Daily	Atherosclerosis risk markers	1 working day	Except Sundays and Public Holidays
Apolipoprotein B	M: 0.55 - 1.40 g/L F: 0.55 - 1.25 g/L	S	Turbidimetry	Daily	Atherosclerosis risk markers	1 working day	Except Sundays and Public Holidays
Ascitic fluid- LDH	<60% of plasma total LDH	AF	IFCC, Lactate to pyruvate	On arrival	Body fluid	24 hours	
Ascitic fluid - Glucose	>60% of plasma glucose	AF	Hexokinase	On arrival	Body fluid	24 hours	
Ascitic fluid - Protein	<50% of plasma protein	AF	Biuret method	On arrival	Body fluid	24 hours	
Aspartate aminotransferase (AST)	M: ≤50 U/L F: ≤35 U/L	HP	IFCC, with Pyridoxal phosphate	On arrival	Liver	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
beta-CrossLaps (CTX)	M(18-30yr): 0.155 - 0.873 µg/L M(31-50yr): 0.093 - 0.630 µg/L M(51-70yr): 0.035 - 0.836 µg/L M(>70yr): ≤0.854 µg/L F(pre-menopause): 0.025 - 0.573 µg/L F(post-menopause): 0.104 - 1.008 µg/L	EP	ECLIA	Every 2 days	Bone marker	2 days	
beta-hydroxybutyrate	<0.4 mmol/L	HP	Enzymatic colorimetric	On arrival	Diabetes	4 hours	
b-human chorionic gonadotropin (hCG)	M: <2 IU/L F(Non-pregnant premenopausal): ≤1 IU/L F(Post-menopausal): ≤7 IU/L	S	ECLIA	On arrival	Pregnancy	4 hours	
Bicarbonate (HCO ₃)	24 - 31 mmol/L	HP	Enzymatic, PEP carboxylase	On arrival	Renal	4 hours	Collected in air-proof container
Bilirubin, direct	≤6.8 µmol/L	HP	Colorimetric, Diazo method	On arrival	Liver	4 hours	Protect from light
Bilirubin, total	≤21 µmol/L	HP	Colorimetric, Diazo method	On arrival	Liver	4 hours	Protect from light

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Blood Gas	pH(Arterial): 7.35 - 7.45 pH(Venous): 7.32 - 7.43 pCO ₂ (Arterial): 32.0 - 48.0 mmHg PCO ₂ (Venous): 6-7 mmHg higher than arterial pCO ₂ pO ₂ (Arterial): 83.0 - 108.0 mmHg	Arterial/ Venous/ Capillary WB	Potentiometry/ Amperometry	On arrival	Blood gas	1 hour	Transport on ice (collected in air-proof container)
CA125	<35 KAU/L	S	CMIA	Daily	Tumour Marker	1 working day	Except Sundays and Public Holidays
CA15.3	<28 KAU/L	S	CMIA	Daily	Tumour Marker	1 working day	Except Sundays and Public Holidays
CA19.9	<37 KAU/L	S	CMIA	Daily	Tumour Marker	1 working day	Except Sundays and Public Holidays
CA72.4	<6.9 KU/L	HP	ECLIA	On arrival	Tumour Marker	4 hours	
Calcium	2.15 - 2.55 mmol/L	HP	NM-BAPTA	On arrival	Metabolic/Bone	4 hours	Included albumin-adjusted calcium
Calcium, ionized	1.15 - 1.33 mmol/L	Ca-balanced HepWB (collected in air-proof container)	Direct ISE	On arrival	Metabolic/Bone	4 hours	Transport on ice
Carboxyhaemoglobin	Non-smokers: <3% Smokers: <10%	Arterial/ Venous/ Capillary WB (collected in air-proof container)	Co-oximetry	On arrival	Co-oximetry	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Carcinoembryonic antigen (CEA)	Non-smokers: <5 µg/L Smokers: <10 µg/L	S	CMIA	Daily	Tumour Marker	1 working day	Except Sundays and Public Holidays
CSF- Glucose	approx. 60% of plasma glucose	CSF	Hexokinase	On arrival	CSF	2 hours	
CSF- Protein	150 - 450 mg/L		Turbidimetry	On arrival	CSF	2 hours	
CSF- Albumin	<0.35 g/L		Turbidimetry	On arrival	CSF	1 working day	
CSF- IgG	<0.034 g/L		Turbidimetry	On arrival	CSF	1 working day	
CSF- IgG Index	<0.8	CSF, S	Turbidimetry	On arrival	CSF	1 working day	
Chloride	98 - 107 mmol/L	HP	Indirect ISE	On arrival	Renal	4 hours	
Cholesterol, total (Fasting)	Desirable <5.18 mmol/L	HP	Cholesterol oxidase/ Peroxidase	On arrival	Lipids	4 hours	8 hours fasting
Cholesterol, total (Non-fasting)	<5.0 mmol/L	HP	Cholesterol oxidase/ peroxidase	On arrival	Lipids	4 hours	
Cholesterol, total to HDL-Cholesterol Ratio (Fasting/ Non-fasting)	Desirable <5.0	HP	Calculated from total Chol & HDL	On arrival	Lipids	4 hours	
CKMB	M: <6.2 µg/L F: <4.9 µg/L	HP	ECLIA	On arrival	Cardiac	2 hours	
Complement C3	0.81 - 1.57 g/L	S	Turbidimetry	Daily	Immune	1 working day	
Complement C4	0.129 - 0.392 g/L	S	Turbidimetry	Daily	Immune	1 working day	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Cortisol	6-10am: 133 -537 nmol/L	HP	ECLIA	On arrival	Hormone	4 hours	
	4-8pm: 68.2 - 327 nmol/L						
C-Reactive protein	<5 mg/L	HP	Immunoturbidimetric	On arrival	Inflammatory marker	4 hours	
Creatine Kinase (CK)	M: 39 - 308 U/L	HP	IFCC, Imidazole buffer	On arrival	Cardiac	4 hours	
	F: 26 - 192 U/L						
Creatinine	M: 62 - 106 µmol/L	HP	Jaffe, Alk. Picrate	On arrival	Renal	4 hours	
	F: 44 - 80 µmol/L						
Creatinine Clearance	M: 0.82 - 1.20 ml/s/sq.m	HP & 24-hr U	Jaffe, Alk. Picrate	Daily	Renal	1 working day	
	F: 0.72 - 1.11 ml/s/sq.m						
Cyclosporine A	Therapeutic (12hr post dose): 100 - 400 µg/L	EW	CMIA	Daily	Immunosuppressants	1 working day	
	(24hr post dose): 100 - 200 µg/L						
	Toxic: >400 µg/L						
Cytomegalovirus IgG	N/A	S	CMIA	Every 2 days	Serology	2 days	
Cytomegalovirus IgM	N/A	S	CMIA	Every 2 days	Serology	2 days	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Dehydroepiandrosterone sulfate (DHEA-S)	M(<11yr): <3.9 µmol/L	S	CMIA	Every 2 days	Hormone	2 days	
	M(11-14yr): 0.5 -6.6 µmol/L						
	M(15-19yr): 1.2 - 10.4 µmol/L						
	M(20-24yr): 6.5 - 14.6 µmol/L						
	M(25-34yr): 4.6 - 16.1 µmol/L						
	M(35-44yr): 3.8 - 13.1 µmol/L						
	M(45-54yr): 3.7 - 12.1 µmol/L						
	M(55-64yr): 1.3 - 9.8 µmol/L						
	M(65-70yr): 6.2 - 7.7 µmol/L						
	F(<11yr): <3.8 µmol/L						
	F(11-14yr): 0.2 - 4.6 µmol/L						
	F(15-19yr): 1.7 - 13.4 µmol/L						
	F(20-24yr): 3.6 - 11.1 µmol/L						
	F(25-34yr): 2.6 - 13.9 µmol/L						
	F(35-44yr): 2.0 - 11.1 µmol/L						

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Dehydroepiandrosterone sulfate (DHEA-S)	F(45-54yr): 1.5 - 7.7 µmol/L		CMIA	Every 2 days	Hormone	2 days	
	F(55-64yr): 0.8 - 4.9 µmol/L						
	F(65-70yr): 0.9 - 2.1 µmol/L						
Digoxin	Therapeutic: 1.0 - 2.6 nmol/L Toxic: >2.6 nmol/L	S	KIMS	On arrival	Therapeutic drug level	4 hours	
Estimated glomerular filtration rate (eGFR)	>60 ml/min/1.73sq.m	HP	Modified MDRD equation	On arrival	Renal	4 hours	
Estradiol (E2)	Follicular: 46 - 607 pmol/L	HP	ECLIA	On arrival	Fertility Hormone	4 hours	
	Ovulation: 315 - 1828 pmol/L						
	Luteal: 161 - 774 pmol/L						
	Menopause: <201 pmol/L						
	Pregnancy (1 st trimester): 789 - >15781 pmol/L						
M: 28 - 156 pmol/L							
Ferritin	M: 30 - 400 µg/L	HP	ECLIA	On arrival	Anaemic marker	4 hours	
	F: 13 - 150 µg/L						
Folate, RBC	Deficient <340 nmol/L	EW	Competitive Immunoassay, FBP	Daily	Anaemic marker	1 working day	
Folate, serum	Deficient <10.0 nmol/L	HP	Competitive Immunoassay, FBP	Daily	Anaemic marker	1 working day	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks	
Follicle stimulating hormone (FSH)	Follicular: 3.5 - 12.5 IU/L	HP	ECLIA	On arrival	Fertility Hormone	4 hours		
	Ovulation: 4.7 - 21.5 IU/L							
	Luteal: 1.7 - 7.7 IU/L							
	Post-menopause: 25.8 - 134.8 IU/L							
	M: 1.5 - 12.4 IU/L							
Free T3	3.1 - 6.8 pmol/L	HP	ECLIA	On arrival	Thyroid Hormone	4 hours	Gestational age specific reference interval please refer to page 42.	
Free T4	12.0 - 21.9 pmol/L	HP	ECLIA	On arrival	Thyroid Hormone	4 hours		
G6PD Quantitative	Age >3 months	EW	Enzymatic	Daily	Anaemia	1 working day		
	Normal: >6.10 U/g Hb							
	Borderline: 2.41 - 6.10 U/g Hb							
	Deficient: <2.41 U/g Hb							
	Age <=3 months							
	Normal: >9.61 U/g Hb							
	Borderline: 3.86 - 9.61 U/g Hb							
	Deficient: <3.86 U/g Hb							
Gamma-glutamyltransferase (GGT)	M: 10 - 71 U/L F: 6 - 42 U/L	HP	IFCC, Enzymatic colorimetric	On arrival	Liver	4 hours		
Globulin	23 - 38 g/L	HP	Calculated from protein & albumin	On arrival	Liver	4 hours		

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Glucose	Fasting: 3.9 - 5.6 mmol/L Random: 3.9 - 7.8 mmol/L	HP/F	Hexokinase	On arrival	Diabetes	4 hours	8 hours fasting. Fluoride bottle must be used if sample deliver from outside lab
Glycohaemoglobin HbA1c	<6.5%	EW	HPLC	Daily	Diabetes	1 working day	
Haptoglobin	0.32 - 1.97 g/L	S	Turbidimetry	Daily	Specific Protein	1 working day	
Hepatitis A virus IgG	N/A	S	CMIA	Every 2 days	Hepatitis Serology	2 days	
Hepatitis A virus IgM	N/A	S	CMIA	Every 2 days	Hepatitis Serology	2 days	
Hepatitis B virus core antibody IgM (HBcoreIgM)	N/A	S	CMIA	Every 2 days	Hepatitis Serology	2 days	
Hepatitis B virus core total antibody (HBcore Ab)	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
Hepatitis B virus envelop antibody (HBeAb)	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
Hepatitis B virus envelop antigen (HBeAg)	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
Hepatitis B virus surface antibody (HBsAb)	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Hepatitis B virus surface antigen (HBsAg) qualitative	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
Hepatitis B virus surface antigen (HBsAg) qualitative	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
Hepatitis C virus antibody (HCV)	N/A	S	CMIA	Daily	Hepatitis Serology	1 working day	Except Sundays and Public Holidays
High density lipoprotein cholesterol (HDL-C) (Fasting)	M: Desirable ≥1.55 mmol/L; At risk <1.04 mmol/L F: Desirable ≥1.55 mmol/L; At risk <1.30 mmol/L	HP	Homogeneous enzymatic colorimetric	On arrival	Lipids	4 hours	8 hours fasting
High density lipoprotein cholesterol (HDL-C) (Non-fasting)	M: >1.03 mmol/L F: >1.29 mmol/L	HP	Homogeneous enzymatic colorimetric	On arrival	Lipids	4 hours	
High sensitive C-Reactive protein (hs-CRP)	<3.0 mg/L	S	Nephelometry	Daily	Atherosclerosis risk marker	4 hours	
Homocysteine	≤ 12.0 μmol/L	EP	Enzymatic	On arrival	Cardiovascular risk	4 hours	Transport on ice
Human Epididymis protein (HE4)	Pre-menopause: ≤70 pmol/L Post-menopause: ≤140 pmol/L	S	CMIA	Every 2 days	Tumour Marker	2 days	
Human growth hormone	M(<11yr): 0.28 - 18.90 mIU/L M(11-17yr): 0.23 - 32.40 mIU/L M(>17yr): <7.41 mIU/L F(<11yr): 0.36 - 23.40 mIU/L	S	ECLIA	Every 2 days	Hormone	2 days	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Human growth hormone	F(11-17yr): 0.37 - 24.15 mIU/L F(>17yr): 0.38 - 29.64 mIU/L	S	ECLIA	Every 2 days	Hormone	2 days	
Human immunodeficiency virus antibody/p24 antigen (HIV Ag/Ab)	N/A	S	CMIA	Daily	Serology	1 working day	Except Sundays and Public Holidays
Immunofixation	N/A	S	Agarose gel electrophoresis	Daily	Paraprotein	5 days	
Immunoglobulin IgA	0.85 - 4.99 g/L	S	Turbidimetry	Daily	Immunoglobulin	1 working day	Except Sundays and Public Holidays
Immunoglobulin IgE, allergen specific	<=0.34 KU/L	S	ImmunoCAP	Twice per week	Allergy panel	3-5 days	
Immunoglobulin IgE, total	<100 KU/L	S	ImmunoCAP	Twice per week	Allergy panel	3-5 days	
Immunoglobulin IgG	6.10 - 16.16 g/L	S	Turbidimetry	Daily	Immunoglobulin	1 working day	Except Sundays and Public Holidays
Allergen specific Immunoglobulin IgG and IgG4	N/A	S	ImmunoCAP	Twice per week	Allergen components	3-5 days	Egg white, Egg yolk, Peanut, Milk & House dust mite
Immunoglobulin IgM	0.35 - 2.42 g/L	S	Turbidimetry	Daily	Immunoglobulin	1 working day	Except Sundays and Public Holidays
Immunoglobulin subtype G4 (IgG4)	0.04 - 0.86 g/L	S	Turbidimetry	Daily	Immunoglobulin	1 working day	Except Sundays and Public Holidays

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Inorganic phosphate	0.81 - 1.45 mmol/L	HP	Phosphomolybdate formation	On arrival	Metabolic/Bone	4 hours	
Insulin	18 - 173 pmol/L	HP	ECLIA	On arrival	Hormone	4 hours	
Iron	M: 11.0 - 28.0 µmol/L F: 6.6 - 26.0 µmol/L	HP	FerroZine method without deproteinization	On arrival	Anaemia	4 hours	
Lactate	0.5 - 2.2 mmol/L						
Lactate	0.5 - 2.2 mmol/L	F	Enzymatic colorimetric	On arrival	Metabolic	4 hours	Transport on ice. Separate from blood cells ASAP
Lactate dehydrogenase (LDH)	M: 135 - 225 U/L F: 135 - 214 U/L	HP	IFCC, Lactate to pyruvate	On arrival	Cardiac	4 hours	
Lipoprotein(a)	<75 nmol/L	S	Immunoturbidimetric	Daily	Atherosclerosis risk marker	1 working day	
Low density lipoprotein cholesterol (LDL-C) (fasting)	Optimal: <2.59 mmol/L Near optimal: 2.59 - 3.34 mmol/L Borderline high: 3.35 - 4.12 mmol/L High: 4.13 - 4.90 mmol/L Very high: >=4.91 mmol/L	HP	Homogeneous enzymatic colorimetric	On arrival	Lipids	4 hours	Direct measurement, 8 hours fasting
Low density lipoprotein cholesterol (LDL-C) (Non-fasting)	<3.0 mmol/L						
Low density lipoprotein cholesterol (LDL-C) (Non-fasting)	<3.0 mmol/L	HP	Homogeneous enzymatic colorimetric	On arrival	Lipids	4 hours	Direct measurement

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Lutinizng hormone (LH)	Follicular: 2.4 - 12.6 IU/L	HP	ECLIA	On arrival	Fertility Hormone	4 hours	
	Ovulation: 14.0 - 95.6 IU/L						
	Luteal: 1.0 - 11.4 IU/L						
	Post-menopause: 7.7 -58.5 IU/L						
	M: 1.7 -8.6 IU/L						
Magnesium	13-20yr: 0.70 - 0.91 mmol/L	HP	Colorimetric, Xylidyl blue	On arrival	Metabolic	4 hours	
	21-60yr: 0.66 - 1.07 mmol/L						
	61-90yr: 0.66 - 0.99 mmol/L						
	>90yr: 0.70 - 0.95 mmol/L						
Methaemoglobin	<=1.5 %	Arterial/Venous/ Capillary WB (collected in air-proof container)	Co-oximetry	On arrival	Co-oximetry	4 hours	
Methotrexate	24hr post dose: Toxic >10.0 umol/L	HP (Without gel, double- spin)	CMIA	Daily	Therapeutic drug level	1 working day	Wrap in foil, Protect from light, double- spin
	48hr post dose: Toxic >1.0 umol/L						
	72hr post dose: Toxic >0.1 umol/L						

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Microalbumin	Random urine: <30 mg/L	U	Immunoturbidimetric	On arrival	Renal	24 hours	
	24 hour urine:						
	Normal: <=28.8 mg/day						
	Micro albuminuria: 28.8 - 288 mg/day						
	Overt albuminuria: >288 mg/day						
Microalbumin to creatinine ratio	<1.92 mg/mmol	U	Calculated from Microalbumin & Creatinine, urinary	On arrival	Renal	24 hours	
Myoglobin	M: 28 - 72 µg/L F: 25 - 58 µg/L	S	ECLIA	Every 2 days	Cardiac marker	2 days	
Neonatal Bilirubin	Full Term Newborn	HW	Optical	On arrival	Neonatal	1 hour	
	up to 24 hours: 34 - 103 µmol/L						
	up to 48 hours: 103 - 171 µmol/L						
	3 - 5 days: 68 - 137 µmol/L						
	Premature Newborn						
	up to 24 hours: 17 - 137 µmol/L						
	up to 48 hours: 103 - 205 µmol/L						
	3 - 5 days: 171 - 239 µmol/L						

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Non-HDL-Cholesterol (Fasting)	Desirable <4.20 mmol/L	HP	Calculated from total Chol & HDL	On arrival	Lipids	4 hours	
Non-HDL Cholesterol (Non-fasting)	<3.9 mmol/L	HP	Calculated from total cholesterol & HDL	On arrival	Lipids	4 hours	
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)	Rule out acute CHF: <35.5 pmol/L	HP	ECLIA	On arrival	Cardiac marker	4 hours	
	Age stratified cutoff for acute CHF						
	<50yr: >53.3 pmol/L						
	50-75yr: >106.6 pmol/L						
	>75yr: >213.1 pmol/L						
Osmolality, plasma	284 - 306 mOsm/kg	HP	Freezing point depression	On arrival	Metabolic	4 hours	
Osmolality, urine	50 - 1200 mOsm/kg	U	Freezing point depression	On arrival	Metabolic	4 hours	
Osteocalcin	9 - 42 µg/L	EP	ECLIA	Every 2 days	Bone marker	2 days	
Parathyroid hormone (PTH)	1.6 - 6.9 pmol/L	EP	ECLIA	On arrival	Parathyroid	4 hours	
Phenytoin	Therapeutic: 39.6 - 79.2 µmol/L	S	KIMS	On arrival	Therapeutic drug level	4 hours	
Pleural fluid- Adenosine deaminase	<35 U/L	PF	Enzymatic	On arrival	Body fluid	4 hours	
Pleural fluid- Glucose	>50% of plasma glucose	PF	Hexokinase	On arrival	Body fluid	4 hours	
Pleural fluid- Protein	<50% of plasma protein	PF	Biuret method	On arrival	Body fluid	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Pleural fluid- Lactate dehydrogenase (LDH)	<60% of plasma total LDH	PF	IFCC, Lactate to pyruvate	On arrival	Body fluid	4 hours	
Potassium	3.2 - 4.8 mmol/L	HP	Indirect ISE	On arrival	Renal	4 hours	Separate plasma if sample deliver from outside lab
Prealbumin	0.20 - 0.40 g/L	S	Turbidimetry	Daily	Nutritional assessment	1 working day	Except Sundays and Public Holidays
Procalcitonin	Bacterial infection unlikely <0.15 ng/ml	HP	ECLIA	On arrival	Inflammatory marker	4 hours	
	Systemic or severe localized bacterial infection >2.0 ng/ml						
Progesterone	Follicular: <2.8 nmol/L	HP	ECLIA	On arrival	Fertility Hormone	4 hours	
	Ovulation: <38.1 nmol/L						
	Luteal: 5.8 - 75.9 nmol/L						
	Post-menopause: <0.6 nmol/L						
	M: <0.6 nmol/L						
Prolactin	Non-pregnant: 102 - 496 mIU/L M: 86 - 324 mIU/L	HP	ECLIA	On arrival	Fertility Hormone	4 hours to 1 day	
Prostate specific antigen, free (F-PSA)	<0.93 µg/L	S	CMIA	Daily	Tumour Marker	1 working day	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Prostate specific antigen, total (PSA)	M(<60yr): <4.0 µg/L	S	CMIA	Daily	Tumour Marker	1 working day	
	M(60-69yr): <5.0 µg/L						
	M(70-79yr): <7.1 µg/L						
	M(>79yr): <5.9 µg/L						
Protein electrophoresis	N/A	S	Agarose gel electrophoresis	Daily	Paraprotein	5 days	
Protein, total	66 - 87 g/L	HP	Biuret method	On arrival	Liver	4 hours	
Rheumatoid factor (RF)	<14 KU/L	S	Turbidimetry	On arrival	Arthritis	4 hours	
Rubella virus IgG	N/A	S	CMIA	Daily	Serology	1 working day	Except Sundays and Public Holidays
Rubella virus IgM	N/A	S	CMIA	Every 2 days	Serology	2 days	
SARS-CoV-2 virus IgG quantitative	Negative <50 AU/ml Positive ≥50 AU/ml	S	CMIA	Daily	Serology	1 working day	Except Sundays and Public Holidays
Serum free light chains	Free kappa 3.30 - 19.40 mg/L	S	Turbidimetry	Daily	Paraprotein	1 working day	Except Sundays and Public Holidays
	Free lambda 5.71 - 26.30 mg/L						
	Kappa/Lambda ratio: 0.26 - 1.65						

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Serum IgA heavy light chain pair assay	IgA kappa: 0.588 - 2.984 g/L	S	Turbidimetry	Daily	Paraprotein	1 working day	Except Sundays and Public Holidays
	IgA lambda: 0.432 - 2.035 g/L						
	IgA kappa/lambda ratio: 0.91 - 2.42						
Serum IgG heavy light chain pair assay	IgG kappa: 4.03 - 9.78 g/L	S	Turbidimetry	Daily	Paraprotein	1 working day	Except Sundays and Public Holidays
	IgG lambda: 1.97 - 5.71 g/L						
	IgG kappa/lambda ratio: 0.98 - 2.75						
Serum IgM heavy light chain pair assay	IgM kappa: 0.19 - 1.63 /L	S	Turbidimetry	Daily	Paraprotein	1 working day	Except Sundays and Public Holidays
	IgM lambda: 0.12 - 1.01 g/L						
	IgM kappa/lambda ratio: 1.18 - 2.74						
Serum immunofixation	N/A	S	Agarose gel electrophoresis	Daily	Paraprotein	5 days	
Sirolimus	Therapeutic: 3 - 20 µg/L	EW	CMIA	Daily	Therapeutic drug level	1 working day	
	Toxic: >20 µg/L						
Sodium	134 - 148 mmol/L	HP	Indirect ISE	On arrival	Renal	4 hours	
Soluble Transferrin Receptor (sTfR)	M: 1.80 - 4.70 mg/L F: 1.78 - 4.59 mg/L	S	Immunoturbidimetric	Every 2 days	Anaemia	2 days	
Syphilis Treponema pallidum total antibody (TPAb)	N/A	S	CMIA	Daily	Serology	1 working day	Except Sundays and Public Holidays

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Tacrolimus	Therapeutic: 3 - 20 µg/L Toxic: >25 µg/L	EW	CMIA	Daily	Therapeutic drug level	1 working day	
Testosterone	M(<1yr): 0.4 - 0.7 nmol/L M(1-6yr): 0.1 - 1.1 nmol/L M(7-12yr): 0.1 - 2.4 nmol/L M(13-17yr): 1.0 - 38.5 nmol/L M(18-19yr): 8.6 - 29.0 nmol/L M(20-49yr): 8.6 - 29.0 nmol/L M(>50yr): 6.7 - 25.7 nmol/L F(<1yr): 0.4 - 0.7 nmol/L F(1-6yr): 0.1 - 1.1 nmol/L F(7-12yr): 0.1 - 2.4 nmol/L F(13-17yr): 1.0 - 38.5 nmol/L F(18-19yr): 0.3 - 1.7 nmol/L F(20-49yr): 0.3 - 1.7 nmol/L F(>50yr): 0.1 - 1.4 nmol/L	S	ECLIA	On arrival	Hormone	4 hours	
Thyroglobulin	>=21yr: 3.5 - 77.0 µg/L	S	ECLIA	On arrival	Thyroid	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Thyroid stimulating hormone (TSH)	0.27 - 4.20 mIU/L	HP	ECLIA	On arrival	Thyroid	4 hours	Gestational age specific reference interval please refer to page 42.
Total iron binding capacity (TIBC)	44.8 - 80.6 µmol/L	HP	Calculated from transferrin	On arrival	Anaemic marker	4 hours	
Total procollagen-type 1 N-terminal-propeptide (P1NP)	M: 22 - 87 µg/L F (pre-menopause): 15 - 59 µg/L F (Post-menopause): 16 - 74 µg/L	EDTA Plasma	ECLIA	Every 2 days	Bone marker	2 days	
Total T3	0.54 - 2.96 nmol/L	S	CMIA	Every 2 days	Hormone	2 days	
Total T4	58 - 154 nmol/L	S	CMIA	Every 2 days	Hormone	2 days	
Transferrin	2.0 - 3.6 g/L	HP	Immunoturbidimetric	On arrival	Anaemic marker	4 hours	
Triglycerides (Fasting)	Normal <1.69 mmol/L Borderline high: 1.69 - 2.25 mmol/L High: 2.26 - 5.64 mmol/L Very high: >=5.65 mmol/L	HP	Lipase/Glycerol Kinase/GPO	On arrival	Lipids	4 hours	8 hours fasting
Triglycerides (Non-fasting)	<2.0 mmol/L	HP	Lipase/ Glycerol kinase/ GPD	On arrival	Lipids	4 hours	
Troponin I	M: <0.0342 µg/L F: <0.0156 µg/L	HP	CMIA	On arrival	Cardiac marker	2 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Troponin T	<0.014 µg/L	HP	ECLIA	On arrival	Cardiac marker	2 hours	
Tryptase	<11.0 µg/L	S	ImmunoCAP	On arrival	Tryptase	1 working day	Urgent: 4 hours TAT
Urea	2.8 - 8.1 mmol/L	HP	Enzymatic, Urease	On arrival	Renal	4 hours	
Uric acid	M: 0.20 - 0.42 mmol/L F: 0.14 - 0.34 mmol/L	HP	Enzymatic, Uricase/ Peroxidase	On arrival	Renal/Gout	4 hours	
Urine albumin-to-creatinine ratio	M: <1.92 mg/mmol F: <2.83 mg/mmol	U	Turbidimetry/Jaffe	On arrival	Renal	24 hours	
Urine Bence Jones protein	N/A	U	Agarose gel electrophoresis	Daily	Paraprotein	5 days	preferred 24 hr U, at least 50 mL
Urine immunofixation	N/A	U	Agarose gel electrophoresis	Daily	Paraprotein	5 days	preferred 24 hr U, at least 50 mL
Urine protein-to-creatinine ratio	18-83 years: <0.16 mg/mg	U	Biuret/Jaffe	On arrival	Renal	24 hours	
Valproic acid	Therapeutic: 347 - 693 µmol/L Toxic: >693 µmol/L	S	Enzyme immunoassay	On arrival	Therapeutic drug level	4 hours	
Vancomycin	Therapeutic (peak): 17.3 - 27.6 µmol/L (trough): 3.5 - 6.9 µmol/L	S	KIMS	On arrival	Therapeutic drug level	4 hours	
Vitamin B12	Deficient: <150 pmol/L	HP	ECLIA	On arrival	Anaemic marker	4 hours	

Clinical Chemistry (ext. 8792)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Vitamin D (25-OH) total	Deficient: <50 nmol/L Insufficient: 51 -74 nmol/L Desirable: >= 75 nmol/L Potentially toxic: >250 nmol/L	HP	ECLIA	On arrival	Vitamin	4 hours	
24 hr Urinary calcium	2.5 - 7.5 mmol/day	24-hr U	NM-BAPTA	On arrival	Parathyroid/Renal stones	24 hours	
24 hr Urinary creatinine	M: 9 - 21 mmol/day F: 7 - 14 mmol/day	24-hr U	Jaffe, Alk. Picrate	On arrival	Renal	24 hours	
24 hr Urinary potassium	25 - 125 mmol/day	24-hr U	Indirect ISE	On arrival	Renal	24 hours	
24 hr Urinary protein	<0.14 g/day	24-hr U	Turbidimetry	On arrival	Renal	24 hours	
24 hr Urinary sodium	40 - 220 mmol/day	24-hr U	Indirect ISE	On arrival	Renal	24 hours	
24 hr Urinary inorganic phosphate	13 - 42 mmol/day	24-hr U	Phosphomolybdate formation	On arrival	Renal	24 hours	
24 hr Urinary urea	<580 mmol/day	24-hr U	Enzymatic, Urease	On arrival	Renal	24 hours	

Reference Intervals for Gestational Age-Specific Thyroid Function Tests

Gestation (week)	TSH (mIU/L)	Gestation (week)	Free T4 (pmol/L)	Free T3 (pmol/L)
<= 5	0.38 – 4.84	<= 5	11.6 – 23.0	3.5 – 5.7
>5 - 6	0.22 – 4.11	>5 - 6	11.9 – 23.8	3.5 – 5.8
>6 - 7	0.09 – 3.35	>6 - 7	12.1 – 24.5	3.6 – 5.9
>7 - 8	0.05 – 3.02	>7 - 9	12.1 – 24.5	3.6 – 5.9
>8 - 10	0.03 – 2.88	>9 - 10	11.9 – 23.9	3.6 – 5.9
>10 - 11	0.04 – 2.93	>10 - 11	11.7 – 23.3	3.5 – 5.8
>11 - 12	0.05 – 3.03	>11 - 12	11.4 – 22.8	3.5 – 5.7
>12 - 13	0.06 – 3.14	>12 - 13	11.2 – 22.2	3.5 – 5.7
>13 - 14	0.08 – 3.27	>13 - 14	11.0 – 21.6	3.4 – 5.6
>14 - 15	0.09 – 3.40	>14 - 15	10.7 – 21.0	3.4 – 5.5
>15 - 16	0.11 – 3.52	>15 - 16	10.5 – 20.5	3.4 – 5.4
>16 - 20	0.15 – 3.78	>16 - 20	10.1 – 19.4	3.3 – 5.2
>20 - 32	0.23 – 4.18	>20 - 32	9.2 – 17.4	3.0 – 4.8
>32 - 36	0.31 – 4.54	>32 - 36	9.0 – 17.0	2.9 – 4.6
>36	0.44 – 5.07	>36	9.2 – 17.4	3.0 – 4.6

Source: THYROID vol 30, no. 4, 2000: 598-608 [Gestational Age-specific Thyroid Function Test (GTFT) RIs based on PWH local population study on Roche cobas Elecsys system conducted by Department of Chemical Pathology & Department of Obstetrics & Gynaecology (2016)]

Clinical Chemistry (ext. 8792)

Clinical Haematology (ext. 8795)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
Reticulocyte Count	32-135 x 109/L 0.2-2.0 %	EW	Automated cell counter	On arrival	Haematology	2-4 hours
Ret Hb Content	30.7-39.1 pg	EW	Automated cell counter	On arrival	Haematology	2-4 hours
Blood film review by Hosp. Haematologist	N/A	EW/ Blood Smear	Microscope	On arrival	Haematology	24 hours
E.S.R.	Male ≤60 yrs: 0 - 15 mm/hr Male ≥60 yrs: 0 - 20 mm/hr Female≤60 yrs: 0-20mm/hr Female≥60 yrs: 0-30 mm/hr	EW	Modified Westergren Automated	On arrival	Haematology	2-4 hrs
Haemoglobin pattern (quantification of HbA2, HbF, detection of Hb variants)	HbA2: 2.2-3.3 % HbF: <2.0 %	EW	High Performance Liquid Chromatography	Every Thursday	Haematology	1 week
Malaria Parasites	Negative	EW	Microscopy	On arrival	Haematology	2-4 hours
Malaria p.f./p.v. Antigen by immunoassay	Negative	EW	Pf (HRPII) / Pan (aldolase)	On arrival	Haematology	2-4 hours
Activated partial thromboplastin time	22.6 – 33.2 seconds	C	Clotting assay	On arrival	Haematology	2-4 hours
Prothrombin time (PT) & INR	10.0 – 13.0 seconds	C	Clotting assay	On arrival	Haematology	2-4 hours
Thrombin Time (TT)	16.3-19.2 seconds	C	Clotting assay	On arrival	Haematology	2-4 hours

Clinical Haematology (ext. 8795)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
Fibrinogen (Clauss Assay)	1.6-3.7g/L	C	Von Clauss	On arrival	Haematology	2-4 hours
Fibrinogen degradation products (FDP)	<5µg/mL	C	Latex agglutination	Every Tuesday & Friday	Haematology	2-4 hours
D-dimer (Quantitative)	<500µg/L FEU	C	Immunoturbidimetric assay	On arrival	Haematology	2-4 hours
Antithrombin	79 - 120 %	C	Chromogenic assay	Every Friday	Haematology	1 week
Activated Protein C Resistance (APCR) ratio	0.9 - 1.3	C	Clotting assay	Every Friday	Haematology	1 week
Factor II	70-150%	C	Clotting assay	Every Friday	Haematology	1 week
Factor V	70-150%	C	Clotting assay	Every Friday	Haematology	1 week
Factor VII	70-150%	C	Clotting assay	Every Friday	Haematology	1 week
Factor VIII	70-200%	C	Clotting assay	Every Friday	Haematology	1 week
Factor IX	70-120 %	C	Clotting assay	Every Friday	Haematology	1 week
Factor X	70-150%	C	Clotting assay	Every Friday	Haematology	1 week
Factor XI	60-150%	C	Clotting assay	Every Friday	Haematology	1 week
Factor XII	40-120%	C	Clotting assay	Every Friday	Haematology	1 week
Factor XIII	50-120%	C	Chromogenic assay	Every Friday	Haematology	1 week

Clinical Haematology (ext. 8795)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
Lupus anticoagulant	0.8-1.2	C	Clotting assay	Every Friday	Haematology	1 week
Protein C Activity	77-178%	C	Clotting assay	Every Friday	Haematology	1 week
Free Protein S Ag	Male: 67.5-139% Female: 60-114%	C	Immunoturbidimetric assay	Every Friday	Haematology	1 week
Von Willebrand factor antigen	50-160%	C	Immunoturbidimetric assay	Every Friday	Haematology	1 week
Von Willebrand factor Activity	52-181%	C	Immunoturbidimetric assay	Every Friday	Haematology	1 week
Heparin monitoring (Anti-Xa Assay)	Therapeutic LMWH: 0.5-1.2 IU/mL Prophylactic LMWH: 0.2-0.5 IU/ml	C	Chromogenic assay	Every Tuesday	Haematology	1 week
Hemoclot Thrombin Inhibitor (Dabigatran monitoring)	N/A	C	Clotting assay	Every Tuesday	Haematology	1 week
Rivaroxaban (Xarelto monitoring)	N/A	C	Chromogenic assay	Every Tuesday	Haematology	1 week
Apixaban (Eliquis monitoring)	N/A	C	Chromogenic assay	Every Tuesday	Haematology	1 week
Edoxaban (Lixiana monitoring)	N/A	C	Chromogenic assay	Every Tuesday	Haematology	1 week
Bleeding Time (Platelet function by PFA-100)	N/A	CW&EW	PFA-100	On arrival	Haematology	2-4 hours

Clinical Haematology (ext. 8795)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
VerifyNow Aspirin response	N/A	CW&EW	Turbidometric based optical detection	On arrival	Haematology	2-4 hours
VerifyNow Plavix response	N/A	CW&EW	Turbidometric based optical detection	On arrival	Haematology	2-4 hours
Bone Marrow Reporting by Hosp. Haematologist	N/A	BM	N/A	On arrival	Haematology	2-4 hours
Cytochemistry & Reporting	N/A	BM/EW	N/A	On arrival	Haematology	4-6 hours
Trephine Reporting by Hosp. Haematologist	N/A	BM	N/A	On arrival	Haematology	2 days

*C: Citrated plasma

*MU: Morning urine

*BF: Body fluid

*U: Urine

*BM: Bone marrow

*EW: EDTA Whole blood

*CW: Citrate Whole blood

*S: Serum

Clinical Microbiology (Ext. 8791)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
AFB Stain	N/A	All kinds	Kinyoun stain Auramine O stain	Daily On arrival	TB profile	Routine: 1 day Urgent: 3-6 hours
Amoeba	N/A	Stool	Microscopy	On arrival	Stool	1-2 days
Anaerobic Culture	N/A	All kinds	Culture medium inoculation	On arrival	Bacterial culture	5 days
Blood Culture	N/A	Blood	Broth inoculation	On arrival	Bacterial culture	7 days
Clostridioides difficile Culture	N/A	Stool	Selective medium inoculation	On arrival	Stool	2 days
Culture & Sensitivity	N/A	All kinds	Culture medium inoculation/ Antibiotic disk diffusion	On arrival	Bacterial culture	2-3 days
CPE Screen	N/A	Stool / Rectal swab / others	Selective medium inoculation	On arrival	MDRO Screening	2 days
Fungus Culture	N/A	All kinds	Selective medium inoculation	On arrival	Fungal culture	14 days
Fungus Smear	N/A	All kinds	Lactophenol cotton blue stain Gram's stain	Daily On arrival	Differential staining	Routine: 1 day Urgent: 2-6 hours
Gram Stain	N/A	All kinds	Gram's stain	Daily On arrival	Differential staining	Routine: 1 day Urgent: 2-6 hours
Group B Beta-streptococcus Screen (GeneXpert) & GBS C&ST	N/A	Vaginal / Rectal swab	PCR/Selective medium inoculation / Antibiotic disk diffusion	On arrival	Rapid Nucleic Acid Detection	4 hours

Clinical Microbiology (Ext. 8791)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
H. pylori Culture & Sensitivity	N/A	Gastric biopsy	Selective medium inoculation / Antibiotic disk diffusion	On arrival	Helicobacter	7-10 days
India Ink	N/A	CSF	India Ink Stain	On arrival	Differential staining for Cryptococcus	2 hours
Microscopic Examination of Crystals	N/A	Joint fluid	Microscopic polarization examination	On arrival	Joint fluid	1 day
Microscopy for Demodex	N/A	Eye lashes	Microscopic examination	Prior arrangement required	Microscopic examination	2 hours
MRSA Screen	N/A	Nasal swab / others	Selective medium inoculation / Antibiotic disk diffusion	On arrival	MDRO Screening	2 days
MRSA Screen (GeneXpert) & MRSA C&ST	N/A	Nasal swab / others	PCR/Selective medium inoculation / Antibiotic disk diffusion	On arrival	Rapid Nucleic Acid Detection	4 hours
MTB-Nucleic Acid Detection	N/A	All kinds	PCR	Daily	TB profile	1 day
MTB/RIF resistance (GeneXpert)	N/A	Sputum	PCR	On arrival	Rapid Nucleic Acid Detection	6 hours
Mycoplasma hominis & Ureaplasma urealyticum C&ST	N/A	Genital swab	Strip inoculation	On arrival	STD	2-3 days

Clinical Microbiology (Ext. 8791)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT
Occult Blood	Negative: <50 ng/mL Borderline: 50-99 Positive: ≥100	Stool	Fecal immunochemical test	On arrival	Stool	8-18 hours
Stool routine	N/A	Stool	Microscopic examination	On arrival	Stool	8-18 hours
Trichomonas & Monilia	N/A	Genital Swab	Microscopic examination	On arrival	STD	2 days
Urine routine	N/A	Urine	Automated urine chemistry & cell count analysis	On arrival	Urine	2-4 hours
Pregnancy test	N/A	Urine	Lateral flow assay	On arrival	Urine	2 hours
VRE Screen	N/A	Stool / Rectal swab	Selective medium inoculation	On arrival	MDRO Screening	2 days

Note: For bacterial and fungal culture, a preliminary report will be issued once the pathogenic microorganism is isolated.

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
ADAMTS 13 Antigen & Auto-Antibody	Antigen: Normal 0.32-0.73 (IU/mL) Antibody: Negative <15 (units/mL) Borderline: 15-20 Positive: >20	Citrate plasma	ELISA	Monthly	Immunology	1 month	Freeze double-spin plasma at -80°C if not tested right away
ADAMTS Activity	Normal: 60.6-130.6 (IU/dL)	Citrate plasma	CLIA	1-2 times a week	Immunology	2-5 working days	Freeze double-spin plasma at -80°C if not tested right away
ANCA	Negative: <20 (Titre) Positive: ≥20	Serum	IFA	2 times a week	Immunology	4 working days	
ANCA-MPO & PR3	Negative: <20 (RU/mL) Positive: ≥20	Serum	ELISA	2 times a week	Immunology	4 working days	
Anti-Cardiolipin IgG & IgM	Negative: <12 (U/mL) Positive: ≥12	Serum	ELISA	2 times a week	Immunology	4 working days	
Anti-CCP (cyclic citrullinated peptide)	Negative: ≤5 (RU/mL) Positive: >5	Serum	ELISA	2 times a week	Immunology	4 working days	
Anti-ds DNA	Negative: <100 (IU/mL) Positive: ≥100	Serum	ELISA	3 times a week	Immunology	4 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Anti-ENA Profile by ELISA (Ribosomal P proteins, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1 & Centromeres)	Negative: <1.0 (Index value) Weak Positive: ≥1.0-2.0 Positive: >2.0-5.0 High Positive: >5.0	Serum	ELISA	Weekly	Immunology	7 working days	
Anti-ENA Profile by Immunoblot (Mi-2, Ku, nRNP/Sm, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP-B, PCNA, dsDNA, Nucleosomes, Histones, Rib P protein, AMA, M2, DFS70)	N/A	Serum	Immunoblot	2 times a week	Immunology	4 working days	
Anti-Nuclear Antibody (ANA)	Negative: ≤40 (Titre) Positive: >40	Serum	IFA	Daily (Except Saturdays, Sundays and Public Holidays)	Immunology	2-4 working days	
Anti-PF4 IgG	N/A	Serum	ELISA	Weekly	Immunology	7 working days	
Anti-PM-Scl IgG	Negative: <20 (RU/mL) Positive: ≥20	Serum	ELISA	Weekly	Immunology	7 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Anti-β2 Glycoprotein 1 IgG & IgM	Negative: <20 (RU/mL) Positive: ≥20	Serum	ELISA	2 times a week	Immunology	4 working days	
Aspergillus Galactomannan Antigen	Serum: Negative <0.5 (Index value) Positive ≥0.5 BAL: Negative <1.0 (Index value) Positive ≥1.0	Serum/BAL	ELISA	3 times a week	Immunology	2 working days	
Autoimmune Inflammatory Myopathy (Anti-Mi-2α, Anti-Mi-2β, Anti-TiF1γ, Anti-MDA5, Anti-NXP2, Anti-SAE1, Anti-Ku, Anti-PM-Scl-100, Anti-PM-Scl-75, Anti-Jo-1, Anti-SRP, Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-Ro-52, Anti-cN-1A, Anti-HMGCR)	N/A	Serum	Immunoblot	2 times a week	Immunology	4 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Bacterial Antigen Screen (H.influenza b, Strep B, Pneumococcus, Meningococcus, E. coli)	N/A	CSF	Latex agglutination	On arrival	Immunology	3 hours	
Brucella Agglutination Test	N/A	Serum	Latex agglutination	Daily	Immunology	2 working days	
Chlamydia pneumoniae Ab-IgG & IgM	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
Chlamydia trachomatis Ab-IgG	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
Cryptococcal Antigen	N/A	CSF	Lateral flow assay	On arrival	Immunology	3 hours	
Cryptococcal Antigen	N/A	Serum	Lateral flow assay	On arrival	Immunology	1 working day	
Dengue Virus Ab IgG, IgM and NS1 Rapid Test	N/A	Serum	Lateral flow assay	On arrival	Immunology	4 hours	
EBV Ab IgM & IgG for infectious mononucleosis	N/A	Serum	Immunoblot	3 times a week	Immunology	3 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
EBV Ab-IgA	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
Entamoeba histolytica Ab-IgG	N/A	Serum	ELISA	2 times a week	Immunology	4 working days	
H. pylori Ab-IgG	N/A	Serum	Lateral flow assay	Daily (Except Sundays and Public Holidays)	Immunology	1 working day	
H. pylori Antigen	N/A	Stool	Lateral flow assay	Daily (Except Sundays and Public Holidays)	Immunology	1 working day	
HSV 1 Specific Ab-IgG	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
HSV 2 Specific Ab-IgG	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Legionella Urinary Antigen	N/A	Urine	Lateral flow assay	On arrival	Immunology	4 hours	
Measles Ab-IgG	N/A	Serum	Enzyme immunoassay	2 times a week	Immunology	4 working days (6 hours for pregnancy case)	
Monospot Test (Heterophile Ab-IgM)	N/A	Serum	Lateral flow assay	Daily	Immunology	1 working day	
Parasite Antigen Screen (Giardia, Entamoeba histolytica, Cryptosporidium)	N/A	Stool	Lateral flow assay	Daily (Except Sundays and Public Holidays)	Immunology	1 working day	
Parvovirus B19 Ab-IgG	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
Parvovirus B19 Ab-IgM	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
QuantiFeron-TB Gold	Negative: <0.35 (IU/mL) Positive: ≥0.35 (IU/mL)	Plasma (special tubes required, provided by lab)	ELISA	2 times a week	Immunology	4 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Seminal Fluid Routine Analysis	N/A	Semen	Microscopy	On arrival (service time: 08:00-15:00 except Sundays and Public Holidays)	Immunology	1 working day	
Streptococcus pneumoniae Antigen	N/A	Urine	Lateral flow assay	On arrival	Immunology	4 hours	
Streptococcus pyogenes Group A Antigen	N/A	Throat swab	Lateral flow assay	On arrival	Immunology	2 hours	
Strongyloides Ab-IgG	Negative: <0.8 (Index value) Borderline: 0.8-1.0 Positive: >1.0	Serum	ELISA	2 times a week	Immunology	4 working days	
Syphilis RPR	N/A	Serum	Latex agglutination	Daily (Except Sundays and Public Holidays)	Immunology	1 working day	
Syphilis VDRL	N/A	CSF	Latex agglutination	On arrival	Immunology	4 hours	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Systemic Sclerosis Profile (Anti-Scl-70, Anti-CENP A, Anti-CENP B, Anti-RP11, Anti-RP155, Anti-Fibrillarin, Anti-NOR90, Anti-Th/To, Anti-PM-Scl-100, Anti-PM-Scl-75, Anti-Ku, Anti-PDGFR, Anti-Ro-52)	N/A	Serum	Immunoblot	2 times a week	Immunology	4 working days	
T.P.P.A. for Syphilis	N/A	Serum	Latex agglutination	2 times a week	Immunology	4 working days (6 hours for pregnancy case)	
TPO Antibodies	Negative: <50 (IU/mL) Positive: ≥50	Serum	ELISA	2 times a week	Immunology	4 working days	
TSH Receptor Ab-IgG	Negative: <1 (IU/mL) Positive: ≥1	Serum	ELISA	2 times a week	Immunology	4 working days	

Clinical Immunology (ext. 8796)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Varicella Zoster Virus IgG	N/A	Serum	Enzyme immunoassay	3 times a week	Immunology	3 working days (6 hours for pregnancy case)	
Von Willebrand factor Collagen Binding Activity	41-148%	Citrate plasma	ELISA	Monthly	Immunology	1 month	Freeze double-spin plasma at -80°C if not tested right away
Weil-Felix Test	N/A	Serum	Latex agglutination	Daily	Immunology	2 working days	
Widal Test	N/A	Serum	Latex agglutination	Daily	Immunology	2 working days	
(1,3)-Beta-D-Glucan Test	Negative: ≤0.74 (Index value) Indeterminate: 0.75-1.1 Positive: ≥1.2	Serum	Enzyme-based colorimetric assay	3 times a week	Immunology	3 working days	

Core Laboratory Service

Test Name	Ref. Interval	Specimen	Method	Test Frequency	TAT (upon arrival of the specimen)	Panel
CSF routine analysis (WBC, D/C, RBC, Glucose, Protein)	MNC <5/uL Glucose: Protein:	CSF	Microscopic examination	On arrival	2 hours	CSF
Pleural fluid routine analysis (pH, WBC, D/C, RBC, Glucose, Protein)	Exudate: WBC >1000/uL RBC >1000/uL Transudate: WBC <1000/uL RBC <1000/uL Glucose: Protein: pH: >7.64	Pleural fluid	Microscopic examination	On arrival	2-4 hours	Pleural fluid
Ascitic fluid routine analysis (pH, WBC, D/C, RBC, Glucose, Protein)	Peritonitis: WBC >500/uL Glucose: Protein: pH: >7.36	Ascitic fluid	Microscopic examination	On arrival	2-4 hours	Ascitic fluid
Joint fluid analysis (WBC, RBC)	WBC <200/uL Septic arthritis ≥50000/uL	Joint fluid	Microscopic examination	On arrival	2-4 hours	Joint fluid
Other body fluid analysis (pH, WBC, D/C, RBC)	N/A	Body fluid	Microscopic examination	On arrival	2-4 hours	Other body fluid

Stem Cell (ext. 8412)

Test Name	Ref. Interval	Specimen	Test Frequency	Panel	Pledge TAT
Hematopoietic Progenitor Cells (Apheresis) Processing and Cryopreservation	N/A	Fresh *HPC(A)	Prior arrangement required	HPC(A)	2 days (preliminary report) 14 days (final report)
Hematopoietic Progenitor Cells (Apheresis) Thawing	N/A	Frozen HPC(A)	Prior arrangement required	HPC(A)	2 days (preliminary report) 14 days (final report)

*HPC(A): Hematopoietic Progenitor Cells (Apheresis)

Flow Cytometry (ext. 8412)

Test Name	Ref. Interval	Specimen*	Method	Test Frequency	Panel	Pledge TAT
Immunophenotyping By Flow Cytometry						
CD34 enumeration	N/A	EW	Flow Cytometry	Prior arrangement required	Flow Cytometry	6 hours
Lymphocyte subsets study including CD4 cell count	CD3+ T cells: 56.3 - 86.0 % 764 - 2620 cells/μL CD3+/CD4+ T cells: 25.2 - 53.0 % 354 - 1526 cells/μL CD3+/CD8+ T cells: 17.9 - 46.0 % 318 - 1457 cells/μL CD19+ B cells: 6.2 - 19.2 % 103 - 666 cells/μL CD3-CD56+ NK cells: 6.6 - 28.6 % 89 - 621 cells/μL	EW	Flow Cytometry	Daily	Flow Cytometry	2 days
Leukaemia and lymphoma Immunophenotyping	N/A	EW/BM/BF	Flow Cytometry	Daily	Flow Cytometry	2 days
Lymphocytosis work-up	N/A	EW	Flow Cytometry	Daily	Flow Cytometry	2 days
Minimal residual disease testing	<0.01% of MRD cells in all WBCs	EW/BM	Flow Cytometry	Daily	Flow Cytometry	2 days
Red cell study						
PNH analysis	<1% of PNH clones detected	EW	Flow Cytometry	Daily	Flow Cytometry	2 days
EMA binding test	<20% reduction of mean florescence intensity from controls	EW	Flow Cytometry	Daily	Flow Cytometry	2 days

Flow Cytometry (ext. 8412)

Test Name	Ref. Interval	Specimen *	Method	Test Frequency	Panel	Pledge TAT
Fetal red cells in maternal circulation	N/A	EW	Flow Cytometry	Daily	Flow Cytometry	2 days
Platelet study						
GPIIb/IIIa and GP1b/V/IX detection	Normal expression of CD41, CD42b and CD61	EW & C	Flow Cytometry	Daily	Flow Cytometry	2 days
Basophil activation test						
Autologous serum PEG	<5% CD63+/CD203c in basophils	EW & S	Flow Cytometry	Daily	Flow Cytometry	1 day
Food allergens						
Egg white, egg yolk, cow milk, casein, codfish, shrimp, alpha-gal-HAS, peanut, nAra h 2 peanut, cashew nut	<15% CD63+ in basophils (<10% CD63+ in basophils for nAra h 2 peanut)	EW	Flow Cytometry	Daily	Flow Cytometry	1 day

*EW: EDTA Whole blood

*BM: Bone marrow

*BF: Body fluid

*C: Citrated plasma

*S: Serum

Sleep Test Laboratory (ext. 8702)

Test Name	Test Frequency	Pledge TAT	Remarks
Polysomnography	Prior arrangement required	Within 3 working days	Overnight hospitalisation required
Auto C-PAP	Prior arrangement required	1 working day	Overnight hospitalisation required
Oximetry	Prior arrangement required	1 working day	Overnight hospitalisation required
TcCO ₂	Prior arrangement required	1 working day	Overnight hospitalisation required
Somfit	Prior arrangement required	1 working day	Home Sleep Test

HISTOPATHOLOGY AND CYTOLOGY DIVISION

Histopathology (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Routine histology	Surgical tissue	Fix in adequate 10% buffered formalin #	1-3 working days Large or complex specimens may take longer	** For mastectomy / lumpectomy cases, please write down the specimen excision time AND time immersed into formalin fixative where applicable.
Urgent quick section (by rapid tissue processing)	Small biopsy only. Larger specimens cannot be rapid-processed	Fix in adequate 10% buffered formalin #	A preliminary report will be provided on the same day	1. Double charge applies 2. Service is only available to specimens received by lab before 11:30am
Immunohistochemical (IHC) staining	Tissue or paraffin block or tissue mounted on glass slides	Formalin-fixed tissue	1-5 working days	Please contact lab for further information
Cancer Molecular Analysis Panels	Tissue or paraffin block or tissue mounted on glass slides	Formalin-fixed tissue	7-14 working days	Please contact lab for further information on the tests included in various cancer molecular analysis panels.
Enzyme study	Muscle biopsy	Send fresh, DO NOT FIX IN FORMALIN Store and transport at 4°C as soon as possible	Send-out test	Please contact lab for further information
Electron Microscopy study (EM)	Renal biopsy	Send fresh, DO NOT FIX IN FORMALIN Store and transport at 4°C as soon as possible (DO NOT FREEZE)	Send-out test	Please contact lab for further information

Histopathology (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Immunofluorescence Study (IF)	Skin biopsy	Send fresh, DO NOT FIX IN FORMALIN Store and transport at 4°C as soon as possible (DO NOT FREEZE)	Send-out test	Please contact lab for further information
Case consultation / review	Stained or unstained slides / paraffin blocks from external source	Room temperature	1-5 working days	Please contact lab to confirm exact charges. Please provide sufficient extra unstained slides for additional testing if required. Submitted slides and paraffin blocks will be returned to source after reporting.

Frozen Section (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Frozen section	Intra-operative surgical tissue	Send fresh, DO NOT FIX IN FORMALIN	1. Verbal result within 30 minutes from specimen reception 2. Full report: 1-3 working days 3. For larger specimen issue of full report may take longer	1. Advanced booking is required. 2. Frozen section performed outside office hours will be charged double.

- Office hours: 8am-6pm (Mon-Sat); Closed on Sundays and Public Holidays
- For fresh specimen, please contact within office hours 8am-6pm.
- # Please contact Lab for the issue of formalin-containing bottles.

Cytology - Gynaecological (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Pap smear (Liquid based Pap Test)	Brushed endocervical / vaginal cells placed into the liquid based collection vial with preservation fluid	Store and transport at room temperature	8 working days	1. Please contact Lab for issue of liquid based collection vial (vial and brush) 2. Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history
Pap smear (Conventional method)	Brushed endocervical / vaginal cells smeared on a microscopic glass slide and fixed immediately with cytofix spray	Store and transport at room temperature	8 working days	1. Please contact Lab for issue of cytofix spray 2. Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history
Human Papilloma Virus (HPV) - HPV PCR - HPV Genotyping	Cervical cells from cervix preserved in liquid based collection vial	Store and transport at room temperature	5 - 7 working days	3. Please contact Lab for issue of liquid based collection vial (vial and brush) 4. Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history

Cytology – Non-gynaecological (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Body cavity fluid for cytology	Peritoneal, pelvic, pleural, thoracic cavity and chest fluid	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	
Bronchial-alveolar lavage	Lavage from bronchio-alveolar spaces	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	
Bronchial washing	10 ml. of warm sterile buffered saline washing of cells washed from the bronchi through a fiberoptic bronchoscope	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	
Brushing (bronchial, common bile duct, etc)	Cellular material obtained by brushing and swiped on microscopic slides	- Fix smear/ slide IMMEDIATELY in a container of 95% alcohol or using Cytospray. - Keep brush in a separate bottle filled with 50% alcohol. - Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	Do not discard brush as there may be residual cells useful for diagnosis
Cerebro-spinal fluid (CSF)	Fluid drained from lumbar puncture or brain ventricles	- Urgent transport to Lab is essential as the cells degenerate rapidly. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	
Fine Needle aspiration (FNA)	Materials collected by fine needle aspiration and spread on slides	- Fix slides IMMEDIATELY in a container of 95% alcohol or using Cytospray. - Any residual material in the needle or syringe may be rinsed into FNA bottle.	1-3 working days	Please contact Lab for the issue of FNA fixative-containing bottles

Cytology – Non-gynaecological (ext. 8839)

Test Name	Specimen	Storage & Transport	Pledged TAT	Notes
Peritoneal washing	Washings from peritoneum	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	
Sputum	Early morning "deep cough" sputum	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	Use sterile container
Urine	Voided urine	- Deliver to Lab immediately. - After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.	1-3 working days	

Office hours: 8am-6pm (Mon-Sat); Closed on Sundays and Public Holidays

MOLECULAR PATHOLOGY DIVISION

Infectious Disease (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
EBV DNA Quantitative PCR	N/A	EW	Quantitative real-time PCR	2 times a week	Viremia, therapeutic monitoring	4 working days	
HBV DNA Quantitative PCR	N/A	EW	Quantitative real-time PCR	2 times a week	Viremia, therapeutic monitoring	7 working days	
CMV DNA Quantitative PCR	N/A	EW	Quantitative real-time PCR	On arrival	Viremia, therapeutic monitoring	1-2 working days	
HIV-1 RNA Quantitative PCR	N/A	EW	Quantitative real-time PCR	2 times a week	Viremia, therapeutic monitoring	7 working days	
HCV RNA Quantitative PCR	N/A	EW	Quantitative real-time PCR	2 times a week	Viremia, therapeutic monitoring	4 working days	
HBV YMDD Mutation	N/A	EW	PCR & sequencing	On arrival	Viral resistance	7 working days	
HBV ADV and ETV Drug Resistance	N/A	EW	PCR & sequencing	On arrival	Viral resistance	7 working days	
HCV RNA Genotyping	N/A	EW	RT-PCR & sequencing	On arrival	Viral resistance	7 working days	
High-Risk HPV DNA PCR	N/A	Autocyte, ThinPrep, others	Real-time PCR	2 times a week	Cervical screening, HPV infection	5 working days	
HPV DNA Genotyping	N/A	Autocyte, ThinPrep, others	Real-time PCR & next-/ third-generation sequencing	2 times a week	Cervical screening, HPV infection	7 working days	
Chlamydia trachomatis PCR	N/A	Genital swab, urine	Real-time PCR	On arrival	STD screening	4 working days	
Neisseria gonorrhoeae PCR	N/A	Genital swab, urine	Real-time PCR	On arrival	STD screening	4 working days	

Infectious Disease (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Real-time Reverse Transcription PCR for SARS-CoV-2	N/A	Respiratory specimens	Real-time RT-PCR	On arrival	SARS-CoV-2 infection	1-2 working days	
Respiratory Pathogen Panel by Multiplex PCR	N/A	Respiratory specimens	Real-time PCR	On arrival	Respiratory tract infection (bacterial & viral)	1-2 working days	
Pneumonia Panel by Multiplex PCR	N/A	Respiratory specimens	Real-time PCR	On arrival	Pneumonia (bacterial & viral)	1-2 working days	
Influenza A virus subtype H5 PCR	N/A	Respiratory specimens	Real-time RT-PCR	On arrival	Influenza	1-2 working days	Please consult our Clinical Microbiologists/ Infection Control Unit
SARS-CoV-2/Flu A & B/RSV PCR	N/A	Respiratory specimens	Real-time RT-PCR	On arrival	Influenza	1-2 working days	
Macrolide-Resistant Mycoplasma pneumoniae PCR	N/A	Respiratory specimens	Real-time RT-PCR	On arrival	Atypical pneumonia	1-2 working days	
Pneumocystis jirovecii PCR	N/A	Respiratory specimens	Semi-quantitative real-time PCR	On arrival	PCP pneumonia	1-2 working days	
Measles virus PCR	N/A	Respiratory specimens	Real-time RT-PCR	On arrival	Measles	1-2 working days	
Enteric Pathogens Detection by Multiplex PCR	N/A	Stool	Real-time RT-PCR	On arrival	Gastroenteritis	1-2 working days	

Infectious Disease (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Viral Enteric Pathogens PCR (Norovirus & Rotavirus)	N/A	Stool	Real-time RT-PCR	On arrival	Gastroenteritis	1-2 working days	
Clostridium (Clostridioides) difficile toxin PCR	N/A	Stool	Real-time RT-PCR	On arrival	Gastroenteritis	1-2 working days	
Meningitis/ Encephalitis Pathogen Detection by Multiplex PCR	N/A	CSF	Real-time RT-PCR	On arrival	Meningitis/ encephalitis	1 working day	
Mosquito-borne Pathogen Detection by Multiplex PCR	N/A	serum/ EDTA plasma (PPT) AND EDTA whole blood	Real-time PCR	On arrival	Mosquito-borne disease	1-2 working days	
Pathogen identification by direct sequencing	N/A	Varies	Next-/ third-generation sequencing	On arrival	Targeted/ non-targeted metagenomics	7 working days	Please Consult our Clinical Microbiologists

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Myeloid Panel by NGS	N/A	EW, BM	NGS	once a week	Myeloid Leukaemia	1 month	
Fusion Panel by NGS	N/A	EW, BM	NGS	once a week	Haematological neoplasm	1 month	
MRD Single Variant (by NGS)	N/A	EW, BM	NGS	once a week	Haematological neoplasm	2-4 weeks	
Constitutional Cytogenetics	N/A	EW, Heparin blood	Karyotyping	On arrival	Cytogenetics	7-10 working days	
Cancer Cytogenetics	N/A	BM in culture medium	Karyotyping	On arrival	Cytogenetics	Less than 18 working days	
RUNX1::RUNX1T1 RT-PCR - t(8;21)	N/A	EW, BM	Conventional RT-PCR	On arrival	Acute Myeloid Leukaemia	2-4 working days	
RUNX1::RUNX1T1 quantitative RT-PCR - t(8;21)	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Acute Myeloid Leukaemia	7 working days	
FLT3-ITD & TKD Mutation	N/A	EW, BM	PCR + Fragment Analysis / Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
NPM1 exon 12 Mutation	N/A	EW, BM	PCR + Fragment Analysis / Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
CBFB::MYH11 (inv 16) RT-PCR	N/A	EW, BM	Conventional RT-PCR	On arrival	Acute Myeloid Leukaemia	2-4 working days	

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
CBFB::MYH11 Type A quantitative RT-PCR	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Acute Myeloid Leukaemia	7 working days	
IDH1 and IDH2 hotspots Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
IDH1 R132 Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
IDH2 R140 & R172 Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
CEBPA Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Myeloid Leukaemia	3-5 working days	
KIT exon 17 D816V Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Myeloid Leukaemia	2-4 working days	
MRD Single Variant (by ddPCR)	N/A	EW, BM	ddPCR	On arrival	Haematological neoplasm	7-10 working days	(2-3 months for new assay)
BCR::ABL1 p190 & p210 RT-PCR	N/A	EW, BM	Conventional RT-PCR	On arrival	Acute Lymphoblastic Leukaemia Chronic Myeloid Leukaemia	2-4 working days	
BCR::ABL1 p210 RT-PCR - t(9;22)	N/A	EW, BM	Conventional RT-PCR	On arrival	Acute Lymphoblastic Leukaemia Chronic Myeloid Leukaemia	2-4 working days	
BCR::ABL1 Multiplex RT-PCR (atypical variants)	N/A	EW, BM	Conventional RT-PCR	On arrival	Acute Lymphoblastic Leukaemia Chronic Myeloid Leukaemia	3-5 working days	

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
BCR::ABL1 p190 quantitative RT-PCR	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Acute Lymphoblastic Leukaemia	7 working days	
BCR::ABL1 p210 quantitative RT-PCR	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Chronic Myeloid Leukaemia	7 working days	
BCR::ABL1 p190/ p210 Kinase Domain Mutation	N/A	EW, BM	PCR + Sanger sequencing	On arrival	Acute Lymphoblastic Leukaemia Chronic Myeloid Leukaemia	3-5 working days	
PML::RARA L and S-isoform RT-PCR	N/A	EW, BM	Conventional RT-PCR	On arrival	Promyelocytic	2-4 working days	
PML::RARA L-isoform bcr1 / bcr2 quantitative RT-PCR	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Promyelocytic	7 working days	
PML::RARA S-isoform bcr3 quantitative RT-PCR	N/A	EW, BM	Real-time quantitative RT-PCR	once a week	Promyelocytic	7 working days	
CLL FISH Panel	N/A	EW, BM	FISH	2 times a week	Chronic Lymphocytic Leukaemia / Lymphoma	5-7 working days	
TP53 Mutation (Full gene)	N/A	EW, BM	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	
CLL FISH + TP53 Mutation (Combo)	N/A	EW, BM	FISH / NGS	2 times a week/ once a week	Chronic Lymphocytic Leukaemia / Lymphoma	5-7 working days and 1 month	
IGHV Somatic Hypermutation * (blood)	N/A	EW, BM	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
TCR gene rearrangement (T-cell clonality) * (blood)	N/A	EW, BM	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	
IGH / IGK detection (B-cell clonality) * (blood)	N/A	EW, BM	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	
IG and TCR detection(B+T cell clonality)- Blood	N/A	EW, BM	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	
IG and TCR detection(B+T cell clonality)- FFPE	N/A	FFPE	NGS	once a week	Chronic Lymphocytic Leukaemia / Lymphoma	1 month	
MM FISH Panel	N/A	BM	FISH	2 times a week	Multiple Myeloma	7-10 working days	
Eosinophilia Panel	N/A	EW, BM + Clotted blood	FISH / Conventional RT-PCR	On arrival	Myeloid and Lymphoid Neoplasms with eosinophilia	5-7 working days	

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
MPD Panel - BCR::ABL1 p190 & p210 RT-PCR + Ph-reflex	N/A	EW, BM	Conventional RT-PCR / Allele-specific PCR + PCR-RFLP / PCR-Fragment Analysis/ PCR + Sanger Sequencing	On arrival	Myeloproliferative Neoplasm/Disorders	3-5 working days	
Ph-MPD Panel – JAK2 exon 14 V617F, CALR exon 9, MPL exon 10 S505 and W515 (reflex testing)	N/A	EW, BM	Allele-specific PCR + PCR-RFLP / PCR-Fragment Analysis/ PCR + Sanger Sequencing	On arrival	Myeloproliferative Neoplasm/Disorders	7 working days	
JAK2 exon 14 V617F Mutation	N/A	EW, BM	Allele-specific PCR + PCR-RFLP	On arrival	Myeloproliferative Neoplasm/Disorders	2-4 working days	
JAK2 exon 12 Mutation	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Myeloproliferative Neoplasm/Disorders	2-4 working days	
CALR exon 9 Mutation	N/A	EW, BM	PCR-Fragment Analysis (Sanger Sequencing if necessary)	On arrival	Myeloproliferative Neoplasm/Disorders	2-4 working days	
MPL exon 10 S505 and W515 Mutation	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Myeloproliferative Neoplasm/Disorders	2-4 working days	
MDS FISH Panel	N/A	EW, BM	FISH	2 times a week	Myelodysplastic Syndrome	5-7 working days	

Molecular Haematopathology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
CXCR4 Mutation	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Haematological neoplasm	3-5 working days	
CSF3R exon 14 and 17 Mutation	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Haematological neoplasm	3-5 working days	
STAT3 & STAT5b Mutation	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Haematological neoplasm	3-5 working days	
BRAF Mutation (exon 15 hotspots)	N/A	EW, BM	PCR + Sanger Sequencing	On arrival	Haematological neoplasm	3-5 working days	
PCM1::JAK2 RT-PCR	N/A	EW, BM	Conventional RT-PCR	On arrival	Haematological neoplasm	7 working days	
Factor II (G20210A) Mutation	N/A	EW	Real-time PCR	On arrival	Thrombophilia	1-2 working days	
Factor V Leiden (G1691A) Mutation	N/A	EW	Real-time PCR	On arrival	Thrombophilia	1-2 working days	
Factor II & V Leiden Mutations	N/A	EW	Real-time PCR	On arrival	Thrombophilia	1-2 working days	
MONO Blood FISH (1 probe)	N/A	EW, Marrow blood	FISH	2 times a week	Haematological neoplasm	3-7 working days	Probe list stated on our request form.
DUO Blood FISH (2 probes)	N/A	EW, Marrow blood	FISH	2 times a week	Haematological neoplasm	3-7 working days	Probe list stated on our request form.
TRIO Blood FISH (3 probes)	N/A	EW, Marrow blood	FISH	2 times a week	Haematological neoplasm	3-7 working days	Probe list stated on our request form.
FFPE Blood Panel (4 probes)	N/A	EW, Marrow blood	FISH	2 times a week	Haematological neoplasm	3-7 working days	Probe list stated on our request form.

Molecular Oncology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Comprehensive Genomic Profiling (CGP)	N/A	FFPE +/- Blood Streck tube	NGS	once a week	Solid Tumour	3-4 weeks	Consent form required
Lung Cancer Panel (LCMAP)	N/A	Tumour tissue	Real-time PCR + IHC	2 times a week	Lung Cancer	3-5 working days	IHC is performed by Histopathology Division
EGFR Mutation (exons 18-21 hotspots)	N/A	Tumour tissue	Real-time PCR	2 times a week	Solid Tumour	3-5 working days	
KRAS Mutation (exons 2-4 hotspots)	N/A	Tumour tissue	Real-time PCR	2 times a week	Solid Tumour	3-5 working days	
ALK Kinase Domain Mutation	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	5-7 working days	
PIK3CA Mutation (exons 9 & 20)	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
HER2 Mutation (exon 20)	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
BRAF Mutation (exon 15)	N/A	Tumour tissue	PCR + Fragment Analysis + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
MET exon 14 skipping	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	

Molecular Oncology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
NGS-BREAST PANEL - 9 genes (Blood)	N/A	EW, Clotted blood	NGS	once a week	Solid Tumour	1 month	
Somatic BRCA1 & BRCA2 Mutation by NGS	N/A	Tumour tissue	NGS	once a week	Solid Tumour	1 month	
Combo BRCA gene NGS Panel (Blood and FFPE)	N/A	EW, Clotted blood, Tumour tissue	NGS	once a week	Solid Tumour	1 month	
BRCA1 or BRCA2 or PTEN or TP53 large genomic rearrangement detection by MLPA	N/A	EW, Tumour tissue	MLPA	On arrival	Solid Tumour	5-7 working days	
BRCA1 Known Mutation (Blood)	N/A	EW, Clotted blood	PCR & sequencing	Prior arrangement required	Solid Tumour	5-7 working days	
BRCA2 Known Mutation (Blood)	N/A	EW, Clotted blood	PCR & sequencing	Prior arrangement required	Solid Tumour	5-7 working days	
Targeted genes by NGS (Blood/ FFPE)	N/A	EW, Clotted blood, Tumour tissue	NGS +/- MLPA	once a week	Solid Tumour	1 month	

Molecular Oncology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
Colon Cancer Panel (CCMAP)	N/A	Tumour tissue	Real-time PCR + IHC	2 times a week	Solid Tumour	3-5 working days	IHC is performed by Histopathology Division
NRAS Mutation	N/A	Tumour tissue	Real-time PCR	2 times a week	Solid Tumour	3-5 working days	
Microsatellite Instability (MSI)	N/A	EW, Tumour Tissue	PCR-Fragment Analysis	once a week	Solid Tumour	7-10 working days	
MMR genes by NGS (Blood/ FFPE)	N/A	EW, Clotted blood, Tumour tissue	NGS + MLPA	once a week	Solid Tumour	1 month	
FAP APC & MUTYH Full Gene Mutation by NGS (Blood/ FFPE)	N/A	EW, Clotted blood, Tumour tissue	NGS + MLPA	once a week	Colon Cancer	1 month	
MLH1 / MSH2 / PMS2 / MSH6 / APC / MUTYH Known Mutation (Blood/FFPE)	N/A	EW/ Tumour tissue	PCR + Sanger Sequencing	once a week	Colon Cancer	3-5 working days	
MLH1 / MSH2 / PMS2 / MSH6 / APC / MUTYH large genomic rearrangement detection by MLPA (Blood)	N/A	EW/ Tumour tissue	MLPA	once a week	Colon Cancer	5-7 working days	

Molecular Oncology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
MLH1 / MSH2/ PMS2/ MSH6 Promoter Methylation by MLPA (Blood/ FFPE)	N/A	EW/ Tumour tissue	MLPA	once a week	Colon Cancer	5-7 working days	
Giloma Panel	N/A	Normal and Tumour Tissue	Fish + PCR + Sanger Sequencing + MLPA + IHC	once a week	Brain Cancer	7-10 working days	
Endometrial Cancer Panel (ECMAP)	N/A	FFPE	PCR, Sanger Sequencing, IHC	On arrival	Solid Tumour	5-7 working days	
IDH1 & IDH2 Hotspots Mutation	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
MGMT Promoter Methylation by MLPA	N/A	Noraml and Tumour tissue	MLPA	once a week	Solid Tumour	5-7 working days	
KIT Mutation	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
PDGFRA Mutation	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
KIT & PDGFRA Mutation	N/A	Tumour tissue	PCR + Sanger Sequencing	On arrival	Solid Tumour	3-5 working days	
MONO FFPE FISH (1 probe)	N/A	Tumour tissue	FISH	2 times a week	Solid Tumour	3-7 working days	Probe list stated on our request form

Molecular Oncology (ext. 8779)

Test Name	Ref. Interval	Specimen	Method	Test Frequency	Panel	Pledge TAT	Remarks
DUO FFPE FISH (2 probes)	N/A	Tumour tissue	FISH	2 times a week	Solid Tumour	3-7 working days	Probe list stated on our request form
TRIO FFPE FISH (3 probes)	N/A	Tumour tissue	FISH	2 times a week	Solid Tumour	3-7 working days	Probe list stated on our request form
FFPE FISH Panel (4 probes)	N/A	Tumour tissue	FISH	2 times a week	Solid Tumour	3-7 working days	Probe list stated on our request form.
Other molecular test by special request (genetic test, Structural Rearrangement Breakpoint Mapping....)	N/A	EW, BM, Tissue	PCR/Sanger Sequencing/ MLPA/FISH/ Long-read PCR-free nanopore sequencing	On arrival	N/A	Depends on the test requested	Please contact our division in advance

EW = EDTA whole blood

NGS = Next-generation sequencing

ddPCR = Droplet digital polymerase chain reaction

FFPE = Formalin-fixed, paraffin-embedded tissue

RFLP = Restriction fragment length polymorphism

BM = Bone marrow

RT-PCR = Reverse transcriptase polymerase chain reaction

FISH = Fluorescent in-situ hybridisation

MLPA = Multiplex Ligation-dependent Probe Amplification



HEALTH ASSESSMENT PACKAGES

Health Assessment Schemes

	Male/Female		Female	
	A	B	C	D
Medical History	✓	✓	✓	✓
Complete Physical Examination	✓	✓	✓	✓
Laboratory Investigation				
Complete Blood Count including Platelet	✓	✓	✓	✓
Blood Film	✓	✓	✓	✓
E.S.R.	✓	✓	✓	✓
*Blood Grouping and Rh Typing	✓	✓	✓	✓
*G6PD	✓	-	✓	-
Kidney Function: Urea	✓	✓	✓	✓
Creatinine	✓	✓	✓	✓
Electrolytes: Na, K	✓	✓	✓	✓
Calcium	✓	✓	✓	✓
Liver Function: Albumin adjusted calcium	✓	✓	✓	✓
Bilirubin, total and direct	✓	✓	✓	✓
A. S.T.	✓	✓	✓	✓
A. L.T.	✓	✓	✓	✓
Alkaline phosphatase	✓	✓	✓	✓
Gamma GT	✓	✓	✓	✓



TEST PANELS / PACKAGES

Charge Code	Details	Tests
465-4	Ante-Natal Screening Package	CBP, Blood group & Rh(D), Treponema pallidum Ab, Rubella Ab-IgG, HBsAg, HIV 1 + 2 Ab/p24 Ag
418-2	Arthritis Panel	CBP, ESR, uric acid, albumin, globulin, CRP, RA factor screen, ANA, Anti-CCP IgG
408-5	Cardiology check-up package	CBP, urea, creatinine, sodium, potassium, glucose fasting, ALT, Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, hs-CRP
409-3	Cardiology 1st line intervention	Total cholesterol, HDL cholesterol, LDL cholesterol, Triglycerides, hs-CRP
410-7	Cardiology 2 nd line intervention	Homocysteine, Apo A-1, Apo B, Lp(a), urine microalbumin
90037-4	Child Health Program (plan y - 9 month)	CBP, urine routine, HBsAb screening
90038-2	Child Health Program (plan z - 6 years)	CBP, urine routine, urea, creatinine, total cholesterol, ALT
504-9	Female Hormone Profile 1	E2, LH, FSH
505-7	Female Hormone Profile 2	E2, LH, FSH, Prolactin
506-5	Female Hormone Profile 3	E2, LH
507-3	Female Hormone Profile 4	DHEA-S, E2, FSH, LH, Prolactin
470-1	Lipid Profile	Cholesterol(total), HDL, LDL, Triglyceride, cholesterol/HDL Ratio, Non-HDL cholesterol
468-9	Liver Function Test (LFT 2)	Total & direct bilirubin, ALP, AST, ALT, GGT, Total Protein, Albumin, Globulin
467-1	Pre-Marriage Checkup (Female)	CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HbA1c, Chickenpox IgG, Urine routine
466-2	Pre-Marriage Checkup (Male)	CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HbA1c, Urine routine, Semen Analysis
503-1	Pre-pregnancy Profile	CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, Chickenpox IgG

Charge Code	Details	Tests
469-7	Renal Function Test (RFT 2)	Urea, creatinine, sodium, potassium, chloride, bicarbonate
432-8	Thrombosis panel	Antithrombin, Protein C, Protein S, APCR, Lupus anticoagulant, Anti-cardiolipin Ab
90046-3	Genital Infection Package A	Culture & Sensitivity (including G.C.), Trichomonas & Monilia, Gonococcal & Chlamydia trachomatis-DNA and Mycoplasma hominis/ Ureaplasma urealyticum C&ST (Gel swab for culture, non-gel swab for Mycoplasma, Amplicor STD swab for DNA)
90047-1	Genital Infection Package B	Treponema Pallidum Ab for Syphilis, HIV 1 + 2 Ab/p24 Ag
90058-7	Genital Infection Package C	Culture & Sensitivity (including G.C.), Trichomonas & Monilia, Gonococcal & Chlamydia trachomatis-DNA (Gel swab for culture specimen and Amplicor STD Swab for DNA)
542-1	STD screening (1 st visit) (Female)	CBP, Blood Group & Rh(D), Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL
541-3	STD screening (1 st visit) (Male)	CBP, HBsAg, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL
543-0	STD screening (2 nd visit) (Female / Male)	HBsAg, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL
540-5	Well Women Screening Program	CBP, Urine routine
832-3	Pre-operation coagulation screen	CBP, PT, APTT, PFA-100
833-1	Comprehensive screen for bleeding disorder	CBP, PT, APTT, Fibrinogen, TT, D-Dimer
834-0	VWD panel	VWF Ag, VWF Ac, Factor VIII (F8), VWF Collagen Binding Activity
835-8	Haemophilia panel	CBP, PT, APTT, PFA-100, Factor VIII, Factor IX



GUIDELINES / PATIENT NOTES FOR SPECIAL TESTS

Guidelines / Patient Notes for Special Tests

The general and brief information listed below is for the use by medical personnel when providing instructions to patients on the following special tests. For further details of these tests, please contact the Clinical Laboratory at 2835-8790.

¹³C Urea Breath Test

Fasting must be observed for at least 4 hours prior to testing. In addition, some medications, such as antibiotics, proton-pump inhibitors, etc. may affect test accuracy and should be stopped beforehand. For a comprehensive list of medications, please contact the Clinical Laboratory.

24 HOUR URINE

Patients are requested to visit our Clinical Laboratory and obtain a special specimen container for urine collection. Please advise patients not to touch / pour away the chemicals inside the container. The container should be kept in a cool, dry place for the duration of sample collection. Patients should void and discard a urine sample before commencing collection. Thereafter, all urine voided in the next 24 hours must be collected completely in the container. For creatinine clearance, the patient's height and weight must be obtained with a blood sample within 48 hours before or after urine collection. Sampling during menstruation should be avoided.

Interpretation Chart for EBV Ab-IgM & IgG for Infectious Mononucleosis

	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG
Anti-EBNA-1	-	-	+/-	-	-	-/+	-	-/+
Anti-p22	-	-	+/-	-	-	+	-	+
Anti-VCA	-	-	+	-/+	-	+	+	+
Anti-EA D	-	-	+	+/-	-	-	+	+
Infection status	Negative		Primary / Acute Infection		Convalescence / Past Infection	Reactivated Infection		

Fasting Sample Definition

While there are various different guidelines on the definition of fasting, the Hospital has established a general guideline using information from the American Diabetes Association: a fasting period is defined as "no calorie intake for at least 8 hours". It is recommended that patients do not eat after midnight at the latest, and proceed to the Laboratory for blood tests in the morning. They may have small sips of water while fasting.

Semen Analysis

Semen analysis is done by automated analyzer. Patients are required to abstain from sexual activity 3-5 days prior to sample collection. A suitable container will be provided by the Clinical Laboratory. Semen samples should be obtained by masturbation and collected directly into a container without using condoms. The collection time should be recorded. The sample should reach the Clinical Laboratory within an hour after collection, ideally kept warm to simulate body conditions.



APPENDIX

COMMONLY USED LABORATORY FORMULAE

1. Creatinine Clearance

The creatinine clearance is calculated based on serum and timed urine collection for creatinine measurement. It is an assessment of glomerular filtration rate and hence renal function. The creatinine clearance is more sensitive than serum creatinine in the detection of early glomerular dysfunction. Please note that significant decrease in creatinine clearance may not occur until up to 30% of glomeruli cease to function. Complete and accurately timed urine collection is essential. The height and weight of the patient should be measured for the surface area to be calculated and the creatinine clearance adjusted to the standard body surface area of 1.73m².

$$\text{Creatinine Clearance (ml/min/1.73m}^2\text{)} = \frac{[\text{Urine creatinine (mmol/L)} \times \text{Urine volume (mL)} \times 1.73]}{[\text{Plasma creatinine (mmol/L)} \times \text{Time (min)} \times \text{Body surface area (m}^2\text{)}]}$$

2. Friedewald Equation

$$\text{LDL cholesterol (mmol/L)} = \text{Total cholesterol (mmol/L)} - \text{HDL cholesterol (mmol/L)} - \frac{[\text{Triglyceride (mmol/L)} \times 0.46]}{1}$$

LDL cholesterol result is directly measured rather than calculated from Friedewald Equation unless otherwise specified.

3. Estimated Glomerular Filtration Rate (eGFR)

The modified MDRD formula for Chinese patients is adopted for better correlation with creatinine clearance measurement in the Chinese population. Please note that the modified formula gives a slightly higher eGFR result than the original MDRD formula, especially in females and at high GFR values. The eGFR may not be accurate in people at extremes of body type, e.g. the malnourished and the amputees. Its validity has not been tested across all ethnic groups. The eGFR is not valid in pregnant women and children.

Chronic renal disease is unlikely when the eGFR is >60 ml/min/1.73m² and in the absence of clinical evidence of kidney disorder. Moreover, in persons ≥ 70 years of age, an eGFR value in the range of 45 – 59 ml/min/1.73m², if stable over time and unaccompanied by evidence of renal damage, may be interpreted as typical for this age group and unlikely to be associated with chronic renal disease.

MDRD (Modification of Diet in Renal Disease) formula traceable to IDMS:

$$\text{eGFR (ml/min/1.73m}^2\text{)} = 175 \times [\text{serum creatinine } (\mu\text{mol/L}) \div 88.4]^{-1.154} \times \text{Age}^{-0.203} \times 0.742 \text{ (if female)}$$

Modified MDRD formula for Chinese (J Am Soc Nephrol 17: 2937 – 44, 2006):

$$\text{eGFR (ml/min/1.73m}^2\text{)} = 175 \times [\text{serum creatinine } (\mu\text{mol/L}) \div 88.4]^{-1.234} \times \text{Age}^{-0.179} \times 0.79 \text{ (if female)}$$

4. HbA1c-estimated Average Glucose (eAG)

$$\text{eAG (mmol/L)} = [28.7 \times \text{HbA1c (\%)} - 46.7] \div 18 \text{ or}$$

$$\text{eAG (mmol/L)} = [2870 \times \text{HbA1c (fraction)} - 46.7] \div 18$$

The estimated Average Glucose (eAG) is a new parameter recommended by the American Diabetes Association in 2008 and replaces the mean plasma glucose. The eAG equation is based on the A1c-derived Average Glucose (ADAG) Study published in Diabetes Care 31: 1473 – 8, 2008, which has confirmed the existence of a linear relationship between HbA1c and average blood glucose level. The eAG value is slightly lower than the previously used mean plasma glucose value.

5. Albumin Adjusted Calcium (AACA)

Free calcium, the physiological active form can be estimated using mathematical calculation of total calcium and albumin level.

$$\text{AACA (mmol/L)} = \text{plasma calcium (mmol/L)} + 0.012 [40.3 - \text{plasma albumin (g/L)}]$$

CLINICAL CHEMISTRY UNIT CONVERSION TABLE

Test Name	SI Unit	Conventional Unit	Conversion Factor	
			SI to Conventional	Conventional to SI
Albumin	g/L	g/dL	0.1	10
Amikacin	μmol/L	μg/mL	0.5848	1.71
Ammonia	μmol/L	μg/dL	1.70	0.5872
Bilirubin	μmol/L	mg/dL	0.058	17.1
Calcium	mmol/L	mg/dL	4	0.25
Carbamazepine	μmol/L	μg/mL	0.2364	4.23
Cholesterol, Total	mmol/L	mg/dL	38.7	0.02586
Cortisol	nmol/L	μg/dL	0.0362	27.6
Creatinine	μmol/L	mg/dL	0.0113	88.4
Creatinine Clearance	ml/sec/sq.m	ml/min/1.73sq.m	103.8	0.0096
Cyclosporine A	nmol/L	ng/mL	1.205	0.83
Digoxin	nmol/L	ng/mL	0.7813	1.28
Estradiol	pmol/L	pg/mL	0.2725	3.67
Folate	nmol/L	ng/mL	0.4415	2.265
Free T3	pmol/L	pg/dL	65	0.0154
Free T4	pmol/L	ng/dL	0.0777	12.87
FSH	IU/L	mIU/mL	1	1
Gentamicin	μmol/L	μg/mL	0.4785	2.09
Glucose	mmol/L	mg/dL	18.0	0.0555
HDL-cholesterol	mmol/L	mg/dL	38.7	0.02586
Homocysteine	μmol/L	μg/mL	0.1352	7.396
Inorganic Phosphate	mmol/L	mg/dL	3.097	0.3229
Insulin	pmol/L	μIU/mL	0.1394	7.175
Iron	μmol/L	μg/dL	5.58	0.1791
LDL-Cholesterol	mmol/L	mg/dL	38.7	0.02586
LH	IU/L	mIU/mL	1	1
Magnesium	mmol/L	mg/dL	2.43	0.4114

Test Name	SI Unit	Conventional Unit	Conversion Factor	
			SI to Conventional	Conventional to SI
Microalbumin to creatinine ratio	mg albumin/ mmol creatinine	mg albumin/ g creatinine	8.85	0.113
Nefilmicin	μmol/L	μg/mL	0.4762	2.10
NT-proBNP	pmol/L	pg/ml	8.457	0.118
Osmolality	mmol/kg	mOsmol/kg	1	1
Phenytoin (Dilantin)	μmol/L	μg/mL	0.2525	3.96
Progesterone	nmol/L	ng/mL	0.3145	3.18
Prolactin	mIU/L	ng/ml	0.0472	21.2
Protein	g/L	g/dL	0.1	10
PTH	pmol/L	ng/mL	0.01	100
RBC-G6PD	MU/mol Hb	U/g Hb	15.5	0.0645
Quantitative Test				
Salicylate (Aspirin)	mmol/L	mg/dL	13.812	0.0724
T3	nmol/L	ng/dL	65	0.0154
T4	nmol/L	μg/dL	0.0777	12.87
Testosterone	nmol/L	ng/dL	28.8	0.0347
Theophylline	μmol/L	μg/mL	0.1802	5.55
TIBC	μmol/L	μg/dL	5.5835	0.179
Tobramycin (Nebcin)	μmol/L	μg/mL	0.4673	2.14
Triglycerides	mmol/L	mg/dL	88.57	0.01129
TSH	mIU/L	μIU/mL	1	1
Urea	mmol/L	mg/dL	5.988	0.167
Uric acid	mmol/L	mg/dL	16.95	0.059
Valproic Acid (Epilim)	μmol/L	μg/mL	0.1443	6.93
Vancomycin	μmol/L	μg/mL	1.4493	0.69
Vitamin B12	pmol/L	pg/mL	1.355	0.738
β-hCG	IU/L	mIU/mL	1	1



INDEX

INDEX

24 hr Urinary calcium	41	ANCA-MPO & PR3	50
24 hr Urinary creatinine	41	Anti-Cardiolipin IgG & IgM	50
24 hr Urinary inorganic phosphate	41	Anti-CCP (cyclic citrullinated peptide)	50
24 hr Urinary potassium	41	Anti-ds DNA	50
24 hr Urinary protein	41	Anti-ENA Profile by ELISA	51
24 hr Urinary sodium	41	(Ribosomal P proteins, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1 & Centromeres)	
24 hr Urinary urea	41	Anti-ENA Profile by Immunoblot (Mi-2, Ku, nRNP/Sm, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP-B, PCNA, dsDNA, Nucleosomes, Histones, Rib P protein, AMA, M2, DFS70)	51
Activated partial thromboplastin time	43	Anti-Mullerian Hormone (AMH)	20
Activated Protein C Resistance (APCR) ratio	44	Anti-Nuclear Antibody (ANA)	51
Active B12	19	Anti-PF4 IgG	51
ADAMTS 13 Antigen & Auto-Antibody	50	Anti-PM-Scl IgG	51
ADAMTS Activity	50	Anti-thyroglobulin	20
Adrenocorticotrophic hormone (ACTH)	19	Anti-β2 Glycoprotein 1 IgG & IgM	52
AFB Stain	47	Antithrombin	44
Alanine aminotransferase (ALT)	19	Apixaban (Eliquis monitoring)	45
Albumin	19, 94	Apolipoprotein A1	20
ALK Kinase Domain Mutation	77	Apolipoprotein B	20
Alkaline phosphatase (ALP)	19	Ascitic fluid - Glucose	20
Allergen component IgE	19	Ascitic fluid - Protein	20
Allergen specific Immunoglobulin IgG and IgG4	30	Ascitic fluid routine analysis (pH, WBC, D/C, RBC, Glucose, Protein)	59
Alpha-fetoprotein (AFP)	19	Ascitic fluid- LDH	20
Amikacin	19, 94	Aspartate aminotransferase (AST)	20
Ammonia	19, 94	Aspergillus Galactaomannan Antigen	52
Amoeba	47	Auto C-PAP	62
Amylase	19		
Amylase (drain fluid)	20		
Amylase, pancreatic	20		
Anaerobic Culture	47		
ANCA	50		

Autoimmune Inflammatory Myopathy (Anti-Mi-2 α , Anti-Mi-2 β , Anti-TiF1 γ , Anti-MDA5, Anti-NXP2, Anti-SAE1, Anti-Ku, Anti-PM-Scl-100, Anti-PM-Scl-75, Anti-Jo-1, Anti-SRP, Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-Ro-52, Anti-cN-1A, Anti-HMGCR)	52
Autologous serum PEG	62
Autologous Transfusion	17
Bacterial Antigen Screen (H.influenza b, Strep B, Pneumococcus, Meningococcus, E. coli)	53
BCR::ABL1 Multiplex RT-PCR (atypical variants)	72
BCR::ABL1 p190 & p210 RT-PCR	72
BCR::ABL1 p190 quantitative RT-PCR	73
BCR::ABL1 p190/p210 Kinase Domain Mutation	73
BCR::ABL1 p210 quantitative RT-PCR	73
BCR::ABL1 p210 RT-PCR - t(9;22)	72
beta-CrossLaps (CTX)	21
beta-hydroxybutyrate b-human chorionic gonadotropin (hCG)	21
(1,3)-Beta-D-Glucan Test	58
Bicarbonate (HCO ₃)	21
Bilirubin	94
Bilirubin, direct	21
Bilirubin, total	21
Biopsy (Routine)	63
Biopsy (Urgent quick section by rapid tissue processing)	63
Bleeding Time (Platelet function by PFA-100)	45
Blood Culture	47
Blood film review by Hosp. Haematologist	43
Blood Gas	22

Blood GroupRh (D) typing	17
Body cavity fluid for cytology	66
Bone Marrow Reporting by Hosp. Haematologist	46
BRAF Mutation (exon 15 hotspots)	76
BRAF Mutation (exon 15)	77
BRCA1 Known Mutation (Blood)	78
BRCA1 or BRCA2 or PTEN or TP53 large genomic rearrangement detection by MLPA	78
BRCA2 Known Mutation (Blood)	78
Breast Cancer Markers (ER; PR; Ki67; Her2)	63
Bronchial washing	66
Bronchial-alveolar lavage	66
Brucella Agglutination Test	53
Brushing (bronchial, CBD, etc)	66
C-Reactive protein	24
CA125	22
CA15.3	22
CA19.9	22
CA72.4	22
Calcium	22, 94
Calcium, ionized	22
CALR exon 9 Mutation	75
Cancer Cytogenetics	71
Carbamazepine	94
Carboxyhaemoglobin	22
Carcinoembryonic antigen (CEA)	23
Case consultation / review	64
CBFB::MYH11 (inv 16) RT-PCR	71
CBFB::MYH11 Type A quantitative RT-PCR	72
CD34 enumeration	61

CEBPA Mutation	72
Cerebro-spinal fluid (CSF)	66
Chlamydia pneumoniae Ab-IgG & IgM	53
Chlamydia trachomatis Ab-IgG	53
Chlamydia trachomatis PCR	68
Chloride	23
Cholesterol, Total	94
Cholesterol, total (Fasting)	23
Cholesterol, total (Non-fasting)	23
Cholesterol, total to HDL-Cholesterol Ratio (Fasting/ Non-fasting)	23
CKMB	23
CLL FISH + TP53 Mutation (Combo)	73
CLL FISH Panel	73
Clostridioides difficile Culture	47
Clostridium (Clostridioides) difficile toxin PCR	70
CMV DNA Quantitative PCR	68
Cold Agglutinin	17
Colon Cancer Panel (CCMAP)	79
Combo BRCA gene NGS Panel (Blood and FFPE)	78
Complement C3	23
Complement C4	23
Comprehensive Genomic Profiling (CGP)	77
Constitutional Cytogenetics	71
Consultation and Review	63
Cortisol	24, 94
CPE Screen	47
Creatine Kinase (CK)	24
Creatinine	24, 94
Creatinine Clearance	24, 94

Crossmatch	17
Cryptococcal Antigen	53
CSF routine analysis (WBC, D/C, RBC, Glucose, Protein)	59
CSF- Albumin	23
CSF- Glucose	23
CSF- IgG	23
CSF- IgG Index	23
CSF- Protein	23
CSF3R exon 14 and 17 Mutation	76
Culture & Sensitivity	47
CXCR4 Mutation	76
Cyclosporine A	24, 94
Cytochemistry & Reporting	46
Cytomegalovirus IgG	24
Cytomegalovirus IgM	24
D-dimer (Quantitative)	44
Dehydroepiandrosterone sulfate (DHEA-S)	25, 26
Dengue Virus Ab IgG, IgM and NS1 Rapid Test	53
Digoxin	26, 94
Direct Coombs	17
DUO Blood FISH (2 probes)	76
DUO FFPE FISH (2 probes)	81
E.S.R.	43
EBV Ab IgM & IgG for infectious mononucleosis	53
EBV Ab-IgA	54
EBV DNA Quantitative PCR	68
Edoxaban (Lixiana monitoring)	45
EGFR Mutation (exons 18-21 hotspots)	77
Egg white, egg yolk, cow milk, casein, codfish, shrimp, alpha-gal-HAS, peanut, nAra h 2 peanut, cashew nut	62

Electron Microscopy (EM)	63
EMA binding test	61
Endometrial Cancer Panel (ECMAP)	80
Entamoeba histolytica Ab-IgG	54
Enteric Pathogens Detection by Multiplex PCR	69
Eosinophilia Panel	74
Estimated glomerular filtration rate (eGFR)	26
Estradiol	94
Estradiol (E2)	26
Factor II	44
Factor II (G20210A) Mutation	76
Factor II & V Leiden Mutations	76
Factor IX	44
Factor V	44
Factor V Leiden (G1691A) Mutation	76
Factor VII	44
Factor VIII	44
Factor X	44
Factor XI	44
Factor XII	44
Factor XIII	44
FAP APC & MUTYH Full Gene Mutation by NGS (Blood/ FFPE)	79
Ferritin	26
Fetal red cells in maternal circulation	62
FFPE Blood Panel (4 probes)	76
FFPE FISH Panel (4 probes)	81
Fibrinogen (Clauss Assay)	44
Fibrinogen degradation products (FDP)	44
Fine Needle aspiration (FNA)	66

FLT3-ITD & TKD Mutation	71
Folate	94
Folate, RBC	26
Folate, serum	26
Follicle stimulating hormone (FSH)	27
Free Protein S Ag	45
Free T3	27, 94
Free T4	27, 94
Frozen section	64
FSH	94
Fungus Culture	47
Fungus Smear	47
Fusion Panel by NGS	71
G6PD Quantitative	27
Gamma-glutamyltransferase (GGT)	27
Gentamicin	94
Giloma Panel	80
Globulin	27
Glucose	28, 94
Glycohaemoglobin HbA1c	28
GP1Ib/IIIa and GP1b/V/IX detection	62
Gram Stain	47
Group B Beta-streptococcus Screen (GeneXpert) & GBS C&ST	47
H. pylori Ab-IgG	54
H. pylori Antigen	54
H. pylori Culture & Sensitivity	48
Haemoglobin pattern (quantification of HbA2, HbF, detection of Hb variants)	43
Haptoglobin	28

HBV ADV and ETV Drug Resistance	68
HBV DNA Quantitative PCR	68
HBV YMDD Mutation	68
HCV RNA Genotyping	68
HCV RNA Quantitative PCR	68
HDL-cholesterol	94
Hematopoietic Progenitor Cells (Apheresis) Processing and Cryopreservation	60
Hematopoietic Progenitor Cells (Apheresis) Thawing	60
Hemoclot Thrombin Inhibitor (Dabigatran monitoring)	45
Heparin monitoring (Anti-Xa Assay)	45
Hepatitis A virus IgG	28
Hepatitis A virus IgM	28
Hepatitis B virus core antibody IgM (HBcoreIgM)	28
Hepatitis B virus core total antibody (HBcore Ab)	28
Hepatitis B virus envelop antibody (HBeAb)	28
Hepatitis B virus envelop antigen (HBeAg)	28
Hepatitis B virus surface antibody (HBsAb)	28
Hepatitis B virus surface antigen (HBsAg) qualitative	28
Hepatitis B virus surface antigen (HBsAg) qualitative	29
Hepatitis C virus antibody (HCV)	29
HER2 Mutation (exon 20)	77
High density lipoprotein cholesterol (HDL-C) (Fasting)	29
High density lipoprotein cholesterol (HDL-C) (Non-fasting)	29
High sensitive C-Reactive protein (hs-CRP)	29
High-Risk HPV DNA PCR	68
HIV-1 RNA Quantitative PCR	68
Homocysteine	29, 94
HPV DNA Genotyping	68

HSV 1 Specific Ab-IgG	54
HSV 2 Specific Ab-IgG	54
Human Epididymis protein (HE4)	29
Human growth hormone	29, 30
Human immunodeficiency virus antibody/p24 antigen (HIV Ag/Ab)	30
Human Papilloma Virus (HPV)	65
IDH1 & IDH2 Hotspots Mutation	80
IDH1 and IDH2 hotspots Mutation	72
IDH1 R132 Mutation	72
IDH2 R140 & R172 Mutation	72
IG and TCR detection(B+T cell clonality)- Blood	74
IG and TCR detection(B+T cell clonality)- FFPE	74
IGH / IGK detection (B-cell clonality) *(blood)	74
IGHV Somatic Hypermutation *(blood)	73
Immunofixation	30
Immunofluorescence Study (IF)	64
Immunoglobulin IgA	30
Immunoglobulin IgE, allergen specific	30
Immunoglobulin IgE, total	30
Immunoglobulin IgG	30
Immunoglobulin IgM	30
Immunoglobulin subtype G4 (IgG4)	30
Immunohistochemical (IHC) staining	63
India Ink	48
Indirect Coombs	17
Influenza A virus subtype H5 PCR	69
Inorganic phosphate	31, 94
Insulin	31, 94
Iron	31, 94

JAK2 exon 12 Mutation	75
JAK2 exon 14 V617F Mutation	75
Joint fluid analysis (WBC, RBC)	59
KIT & PDGFRA Mutation	80
KIT exon 17 D816V Mutation	72
KIT Mutation	80
KRAS Mutation (exons 2-4 hotspots)	77
Lactate	31
Lactate dehydrogenase (LDH)	31
LDL-Cholesterol	94
Legionella Urinary Antigen	55
Leukaemia and lymphoma Immunophenotyping	61
LH	94
Lipoprotein(a)	31
Low density lipoprotein cholesterol (LDL-C) (fasting)	31
Low density lipoprotein cholesterol (LDL-C) (Non-fasting)	31
Lung Cancer Panel (LCMAP)	77
Lupus anticoagulant	45
Lutinizng hormone (LH)	32
Lymphocyte subsets study including CD4 cell count	61
Lymphocytosis work-up	61
Macrolide-Resistant Mycoplasma pneumoniae PCR	69
Magnesium	32, 94
Malaria p.f./p.v. Antigen by immunoassay	43
Malaria Parasites	43
MDS FISH Panel	75
Measles Ab-IgG	55
Measles virus PCR	69
Meningitis/Encephalitis Pathogen Detection by Multiplex PCR	70

MET exon 14 skipping	77
Methaemoglobin	32
Methotrexate	32
MGMT Promoter Methylation by MLPA	80
Microalbumin	33
Microalbumin to creatinine ratio	33, 95
Microsatellite Instability (MSI)	79
Microscopic Examination of Crystals	48
Microscopy for Demodex	48
Minimal residual disease testing	61
MLH1 / MSH2 / PMS2 / MSH6 / APC / MUTYH Known Mutation (Blood/FFPE)	79
MLH1 / MSH2/ PMS2/ MSH6 Promoter Methylation by MLPA (Blood/FFPE)	80
MLH1 / MSH2/ PMS2/ MSH6/ APC/ MUTYH large genomic rearrangement detection by MLPA (Blood)	79
MM FISH Panel	74
MMR genes by NGS (Blood/ FFPE)	79
MONO Blood FISH (1 probe)	76
MONO FFPE FISH (1 probe)	80
Monospot Test (Heterophile Ab-IgM)	55
Mosquito-borne Pathogen Detection by Multiplex PCR	70
MPD Panel - BCR::ABL1 p190 & p210 RT-PCR + Ph-reflex	75
MPL exon 10 S505 and W515 Mutation	75
MRD Single Variant (by ddPCR)	72
MRD Single Variant (by NGS)	71
MRSA Screen	48
MRSA Screen (GeneXpert) & MRSA C&ST	48
MTB-Nucleic Acid Detection	48
MTB/RIF resistance (GeneXpert)	48

Muscle Biopsy	63
Mycoplasma hominis & Ureaplasma urealyticum C&ST	48
Myeloid Panel by NGS	71
Myoglobin	33
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)	34
Neisseria gonorrhoeae PCR	68
Neonatal Bilirubin	33
Netilmicin	95
NGS-BREAST PANEL - 9 genes (Blood)	78
Non-HDL Cholesterol (Non-fasting)	34
Non-HDL-Cholesterol (Fasting)	34
NPM1 exon 12 Mutation	71
NRAS Mutation	79
NT-proBNP	95
Occult Blood	49
Osmolality	95
Osmolality, plasma	34
Osmolality, urine	34
Osteocalcin	34
Other body fluid analysis (pH, WBC, D/C, RBC)	59
Other molecular test by special request (genetic test, Structural Rearrangement Breakpoint Mapping....)	81
Oximetry	62
Pap smear (Liquid based Pap Test)	65
Pap smear (Conventional method)	65
Parasite Antigen Screen (Giardia, Entamoeba histolytica, Cryptosporidium)	55
Parathyroid hormone (PTH)	34
Parvovirus B19 Ab-IgG	54

Parvovirus B19 Ab-IgM	55
Pathogen identification by direct sequencing	70
PCM1::JAK2 RT-PCR	76
PDGFRA Mutation	80
Peritoneal washing	67
Ph-MPD Panel - JAK2 exon 14 V617F, CALR exon 9, MPL exon 10 S505 and W515 (reflex testing)	75
Phenytoin	34
Phenytoin (Dilantin)	95
PIK3CA Mutation (exons 9 & 20)	77
Pleural fluid routine analysis (pH, WBC, D/C, RBC, Glucose, Protein)	59
Pleural fluid- Adenosine deaminase	34
Pleural fluid- Glucose	34
Pleural fluid- Lactate dehydrogenase (LDH)	35
Pleural fluid- Protein	34
PML::RARA L and S-isoform RT-PCR	73
PML::RARA L-isoform bcr1 / bcr2 quantitative RT-PCR	73
PML::RARA S-isoform bcr3 quantitative RT-PCR	73
Pneumocystis jirovecii PCR	69
Pneumonia Panel by Multiplex PCR	69
PNH analysis	61
Polysomnography	62
Potassium	35
Prealbumin	35
Pregnancy test	49
Private Donor	17
Procalcitonin	35
Progesterone	35, 95
Prolactin	35, 95

Prostate specific antigen, free (F-PSA)	35
Prostate specific antigen, total (PSA)	36
Protein	95
Protein C Activity	45
Protein electrophoresis	36
Protein, total	36
Prothrombin time (PT) & INR	43
PTH	95
QuantiFeron-TB Gold	55
RBC-G6PD Quantitative Test	95
Real-time Reverse Transcription PCR for SARS-CoV-2	69
Renal Biopsy	64
Respiratory Pathogen Panel by Multiplex PCR	69
Ret Hb Content	43
Reticulocyte Count	43
Rheumatoid factor (RF)	36
Rivaroxaban (Xarelto monitoring)	45
Rubella virus IgG	36
Rubella virus IgM	36
RUNX1::RUNX1T1 quantitative RT-PCR – t(8;21)	71
RUNX1::RUNX1T1 RT-PCR - t(8;21)	71
Salicylate (Aspirin)	95
SARS-CoV-2 virus IgG quantitative	36
SARS-CoV-2/Flu A & B/RSV PCR	69
Seminal Fluid Routine Analysis	56
Serum free light chains	36
Serum IgA heavy light chain pair assay	37
Serum IgG heavy light chain pair assay	37
Serum IgM heavy light chain pair assay	37
Serum immunofixation	37

Sirolimus	37
Skin Biopsy	64
Sodium	37
Soluble Transferrin Receptor (sTfR)	37
Somatic BRCA1 & BRCA2 Mutation by NGS	78
Somfit	62
Special staining	64
Sputum	67
STAT3 & STAT5b Mutation	76
Stool routine	49
Streptococcus pneumoniae Antigen	56
Streptococcus pyogenes Group A Antigen	56
Strongyloides Ab-IgG	56
Syphilis RPR	56
Syphilis Treponema pallidum total antibody (TPAb)	37
Syphilis VDRL	56
Systemic Sclerosis Profile	57
(Anti-Scl-70, Anti-CENP A, Anti-CENP B, Anti-RP11, Anti-RP155, Anti-Fibrillarin, Anti-NOR90, Anti-Th/To, Anti-PM-Scl-100, Anti-PM-Scl-75, Anti-Ku, Anti-PDGFR, Anti-Ro-52)	
T.P.P.A. for Syphilis	57
T3	95
T4	95
Tacrolimus	38
Targeted genes by NGS (Blood/ FFPE)	78
TcCO ₂	62
TCR gene rearrangement (T-cell clonality) *(blood)	74
Testosterone	38, 95
Theophylline	95
Thrombin Time (TT)	43

Thyroglobulin	38
Thyroid stimulating hormone (TSH)	39
TIBC	95
Tobramycin (Nebcin)	95
Total iron binding capacity (TIBC)	39
Total procollagen-type 1 N-terminal-propeptide (P1NP)	39
Total T3	39
Total T4	39
TP53 Mutation (Full gene)	73
TPO Antibodies	57
Transferrin	39
Trephine Reporting by Hosp. Haematologist	46
Trichomonas & Monilia	49
Triglycerides	95
Triglycerides (Fasting)	39
Triglycerides (Non-fasting)	39
TRIO Blood FISH (3 probes)	76
TRIO FFPE FISH (3 probes)	81
Troponin I	39
Troponin T	40
Tryptase	40
TSH	95
TSH Receptor Ab-IgG	57
Type & Screen	17
Urea	40, 95
Urea Breath Test	18
Uric acid	40, 95
Urine	67
Urine albumin-to-creatinine ratio	40
Urine Bence Jones protein	40

Urine immunofixation	40
Urine protein-to-creatinine ratio	40
Urine routine	49
Valproic acid	41
Valproic Acid (Epilim)	95
Vancomycin	40, 95
Varicella Zoster Virus IgG	58
VerifyNow Aspirin response	46
VerifyNow Plavix response	46
Viral Enteric Pathogens PCR (Norovirus & Rotavirus)	70
Vitamin B12	40, 95
Vitamin D (25-OH) total	41
Von Willebrand factor Activity	45
Von Willebrand factor antigen	45
Von Willebrand factor Collagen Binding Activity	58
VRE Screen	49
Warm Agglutinin	17
Weil-Felix Test	58
Widal Test	58
β-hCG	95



For the treatment of cIAI

YOUR CONFIDENT EMPIRIC CHOICE FOR PATIENTS AT RISK

A Novel, fully synthetic **fluorocycline** antibiotic.¹
Broad spectrum activity against many Gram-negative, Gram-positive and anaerobic bacteria.
This includes ESBLs*, CRAB*, VRE*, MRSA*.¹



POTENCY

- XERAVA™ was **2- to 4-fold more potent than tigecycline** in vitro against **Gram-positive and Gram-negative bacteria**.^{1,2}
- **2- to 8-fold more potent** against most **anaerobes**.^{1,2}



WELL-TOLERATED


- Low rates of nausea (6.5%) ,vomiting (3.7%) and AE-related discontinuation (2%).^{1,3}
- No FDA boxed warning.^{1,3}



WEIGHT-BASED DOSING

- **No Therapeutic Drug Monitoring**.^{1,3}
- **No Renal Dose adjustment** required.^{1,3}

All images used in this material are for illustration purposes only.



Dosing and administration for
adult patients (≥18 years of age) with cIAI³



Administer
1 mg/kg



Every
12 hours
by IV infusion



Over approximately
60 minutes

*cIAI: Complicated intra-abdominal infections; ESBLs: Extended-spectrum beta-lactamase; CRAB: Carbapenem-resistant *Acinetobacter baumannii*; VRE: Vancomycin-resistant enterococci; MRSA: Methicillin-resistant *Staphylococcus aureus*.

References: 1. Solomkin JS et al. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance. Future Microbiol. 2019;14:1293-1308. 2. Zhanel GG et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567-588 3. XERAVA™ (eravacycline) Hong Kong Prescribing Information May 2026.

XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/VIAL

Abbreviated Prescribing Information:

ACTIVE INGREDIENT: A yellow to orange, sterile, preservative-free, lyophilized powder in single-dose vials containing 50 mg of eravacycline (equivalent to 63.5 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0. **INDICATIONS AND USAGE:** Treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: in patients 18 years or older. Limitations of Use: XERAVA is not indicated for the treatment of complicated urinary tract infections (CUTI). **DOSAGE AND ADMINISTRATION:** Adult dosage is 1 mg/kg every 12 hours. Administer intravenous infusions of XERAVA over approximately 60 minutes every 12 hours. The recommended duration of treatment for cIAI is 4 to 14 days. The duration of therapy should be guided by the severity and location of infection and the patient's clinical response. **CONTRAINDICATIONS:** Hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity reactions have been reported with XERAVA. **WARNINGS AND PRECAUTIONS:** The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. **Most Common Adverse Reactions:** Occurring at ≥3% in patients were infusion site reactions (7.7%), nausea (6.5%), and vomiting (3.7%). Tetracycline-class Adverse Reactions: XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. These include photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected. **INTERACTIONS:** Concomitant use of strong CYP3A inducers decreases the exposure of eravacycline. Increase XERAVA dose in patients with concomitant use of a strong CYP3A inducer. As tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. **Pregnancy:** The limited available data with XERAVA use in pregnant women are insufficient to inform drug-associated risk of major birth defects and miscarriages. **Lactation:** Breastfeeding is not recommended during treatment with XERAVA and for 4 days (based on half-life) after the last dose. **OVERDOSAGE:** XERAVA should be discontinued and the patient monitored for adverse reactions. **Please read the full prescribing information prior to administration, available from Everest Medicines II (HK) Limited, Unit 2002, 20/F, Nexus Building, 41 Connaught Road, Central, Hong Kong. Version May 2026.**

For reporting adverse events in Hong Kong and Macau, please write to AEreporting@everestmedicines.com
HongKong, Macau_ID_G_NP_202607_00207

For Healthcare Professionals Only.

If there is any enquiries, please contact info.hk@everestmedicines.com





Department of Pathology

Address: Hong Kong Sanatorium & Hospital
1/F, Li Shu Fan Block
2 Village Road, Happy Valley, Hong Kong

Tel: 2835 8790

Fax: 2835 8799

Email: lab@hksh.com

<https://www.hksh-hospital.com/>

© Hong Kong Sanatorium & Hospital; All rights reserved

07/2026



李樹芬醫學基金會
LI SHU FAN
MEDICAL
FOUNDATION

養和醫療集團成員 Members of HKSH MEDICAL GROUP

養和醫院
HONG KONG SANATORIUM & HOSPITAL

養和醫健
HKSH HEALTHCARE

養和東區醫療中心
HKSH EASTERN MEDICAL CENTRE

養和癌症中心
HKSH CANCER CENTRE

養和創新及專業培訓學院
HKSH INSTITUTE FOR INNOVATION & PROFESSIONAL DEVELOPMENT

www.hksh.com